07 December 2020
EMA/CHMP/659998/2020
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Agenda for the meeting on 07-10 December 2020

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

07 December 2020, 09:00 – 18:30, virtual meeting/ room 1C

08 December 2020, 08:30 – 18:30, virtual meeting/ room 1C

09 December 2020, 08:30 – 18:30, virtual meeting/ room 1C

10 December 2020, 08:30 – 18:30, virtual meeting/ room 1C

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 07-10 December 2020. See December 2020 CHMP minutes (to be published post January 2021 CHMP meeting).

1.2. Adoption of agenda

CHMP agenda for 7-10 December 2020

1.3. Adoption of the minutes

ORGAM minutes from meeting held on 30 November 2020.

CHMP minutes from meeting held on 12-15 October 2020.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. selinexor - Orphan - EMEA/H/C/005127

Karyopharm Europe GmbH; treatment of patients with Relapsed Refractory Multiple Myeloma (RRMM).

Scope: Oral explanation,

Draft list of experts for the SAG Oncology meeting scheduled on 30 November 2020 adopted via written procedure on 30 November 2020,

SAG report

Action: Oral explanation to be held on Tuesday, 8 December 2020 at 16:00

List of Outstanding Issues adopted on 15.10.2020. 30.01.2020, 19.09.2019. List of Questions adopted on 24.04.2019.

2.1.2. pemigatinib - Orphan - EMEA/H/C/005266

Incyte Biosciences Distribution B.V.; treatment of locally advanced or metastatic cholangiocarcinoma.

Scope: Oral explanation,

Draft list of experts for the SAG Oncology meeting scheduled on 3 December 2020 adopted

via written procedure by 3 December 2020,

SAG report

Action: Oral explanation to be held on Tuesday, 8 December 2020 at 11:00

List of Outstanding Issues adopted on 17.09.2020. List of Questions adopted on 30.04.2020.

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. WS1844 - Forxiga/Edistride (dapagliflozin) – EMEA/H/C/002322 / EMEA/H/C/004161/WS1844

Astra Zeneca AB

Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin

Scope: "Re-categorisation of the Forxiga/Edistride PASS (D169C00011): Retrospective Cohort Study on the Risk of Diabetic Ketoacidosis (DKA) to determine the effectiveness of additional risk minimisation measures in place for DKA by assessing the impact of the risk minimisation measures on the risk of DKA in T1DM patients who are treated with dapagliflozin in Europe, from a category 1 to category 3 PASS in the RMP Version 20 and removal of the following Annex IID of the PI: Obligation to conduct the following Non-interventional PASS: In order to estimate the incidence of DKA in T1DM dapagliflozin users following implementation of RMMs in Europe, the MAH should conduct and submit the results from an observational cohort study using existing data sources in European countries where dapagliflozin will be launched for T1DM"

Oral explanation

Action: Oral explanation to be held on Tuesday, 8 December 2020 at 14:00

Request for Supplementary Information adopted on 15.10.2020, 23.07.2020.

See 9.1

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. remimazolam - EMEA/H/C/005246

indicated for procedural sedation.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 30.04.2020.

3.1.2. trastuzumab deruxtecan - EMEA/H/C/005124

treatment of unresectable or metastatic HER2-positive breast cancer.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 10.11.2020. List of Questions adopted on 15.09.2020.

3.1.3. hepatitis B surface antigen - EMEA/H/C/005063

prevention of hepatitis B virus infection.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 25.07.2019.

3.1.4. fedratinib - Orphan - EMEA/H/C/005026

Celgene Europe BV; treatment of primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.05.2020.

3.1.5. insulin aspart - EMEA/H/C/004965

treatment of diabetes mellitus.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 27.02.2020.

3.1.6. lenalidomide - EMEA/H/C/005348

treatment of multiple myeloma.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.05.2020.

3.1.7. lenalidomide - EMEA/H/C/005734

treatment of multiple myeloma and Follicular lymphoma.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020.

3.1.8. lenalidomide - EMEA/H/C/005729

treatment of multiple myeloma, myelodysplastic syndromes and follicular lymphoma.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020.

3.1.9. moxetumomab pasudotox - Orphan - EMEA/H/C/005322

AstraZeneca AB; relapsed or refractory hairy cell leukaemia (HCL) after receiving at least two prior systemic therapies.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 30.04.2020.

3.1.10. glucagon - EMEA/H/C/005391

treatment of severe hypoglycaemia in adults, adolescents and children aged 2 years and over, with diabetes mellitus.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 12.11.2020, 17.09.2020. List of Questions adopted on 30.04.2020.

3.1.11. fostemsavir - EMEA/H/C/005011

indicated, in combination with other antiretrovirals, for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.04.2020.

3.1.12. selpercatinib - EMEA/H/C/005375

indicated for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy; advanced RET fusion-positive thyroid cancer who require systemic therapy and who have progressed following prior treatment. As monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.05.2020.

3.1.13. potassium - Orphan - EMEA/H/C/005407

Advicenne S.A.; treatment of distal renal tubular acidosis (dRTA) in patients aged 6 months and older.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 26.03.2020.

3.1.14. sunitinib - EMEA/H/C/005419

treatment of gastrointestinal stromal tumour (GIST), metastatic renal cell carcinoma (MRCC) and pancreatic neuroendocrine tumours (pNET).

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 27.02.2020.

3.1.15. tucatinib - EMEA/H/C/005263

treatment of metastatic breast cancer or brain metastases.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.05.2020.

3.1.16. adalimumab - EMEA/H/C/005188

treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa (HS), Crohn’s disease, paediatric Crohn's disease, ulcerative colitis, uveitis, paediatric uveitis.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 12.11.2020. List of Questions adopted on 23.07.2020.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. idecabtagene vicleucel - Orphan - ATMP - EMEA/H/C/004662

Accelerated assessment

Celgene Europe BV; treatment of multiple myeloma.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 11.09.2020.

3.2.2. bevacizumab - EMEA/H/C/005327

Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.
First line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.07.2020.

3.2.3. bevacizumab - EMEA/H/C/005286

Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.
First line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.05.2020.

3.2.4. bevacizumab - EMEA/H/C/005611

Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.
First line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.07.2020.

3.2.5. cenobamate - EMEA/H/C/005377

for the adjunctive treatment of focal onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic products.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.07.2020.

3.2.6. duvelisib - Orphan - EMEA/H/C/005381

Verastem Europe GmbH; treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) and relapsed or refractory follicular lymphoma (FL).

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted 17.09.2020. List of Questions adopted on 30.04.2020.

3.2.7. dostarlimab - EMEA/H/C/005204

treatment of mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) endometrial cancer (EC).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.06.2020.

3.2.8. ofatumumab - EMEA/H/C/005410

treatment of relapsing forms of multiple sclerosis.

Scope: List of outstanding issues,

list of questions to the SAG

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.05.2020.

3.2.9. berotralstat - Orphan - EMEA/H/C/005138

BioCryst Ireland Limited; prevention of hereditary angioedema (HAE).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.07.2020.

3.2.10. bevacizumab - EMEA/H/C/005556

Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.

First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.

First line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.05.2020.

3.2.11. pitolisant - EMEA/H/C/005117

treatment of excessive day time sleepiness (EDS) in patients with obstructive sleep apnoea (OSA).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.06.2020.

3.2.12. sildenafil - EMEA/H/C/005439

treatment of erectile dysfunction.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.06.2020.

3.2.13. thiotepa - EMEA/H/C/005434

conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT), treatment of solid tumours.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.09.2020.

3.2.14. trastuzumab - EMEA/H/C/005066

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 19.09.2019.

3.2.15. icosapent ethyl - EMEA/H/C/005398

indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 17.09.2020. List of Questions adopted on 26.03.2020.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. bimekizumab - EMEA/H/C/005316

treatment of plaque psoriasis.

Scope: List of questions

Action: For adoption

3.3.2. evinacumab - EMEA/H/C/005449

Accelerated assessment

treatment of homozygous familial hypercholesterolemia (HoFH).

Scope: List of questions

Action: For adoption

3.3.3. icatibant - EMEA/H/C/005083

treatment of hereditary angioedema.

Scope: List of questions

Action: For adoption

3.3.4. glucarpidase - Orphan - EMEA/H/C/005467

Protherics Medicines Development Europe B.V.; treatment of patients at risk of methotrexate toxicity.

Scope: List of questions

Action: For adoption

3.3.5. vosoritide - Orphan - EMEA/H/C/005475

BioMarin International Limited; indicated for the treatment of achondroplasia.

Scope: List of questions

Action: For adoption

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. risperidone- EMEA/H/C/005406

treatment of schizophrenia.

Scope: Letter from the applicant dated 4 December 2020 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in October 2020.

Action: For adoption

List of outstanding issues adopted on 15.10.2020. List of questions adopted on 28.05.2020.

3.4.2. sugammadex - EMEA/H/C/005403

treatment of neuromuscular blockade induced by rocuronium or vecuronium.

Scope: Letter from the applicant dated 3 December 2020 requesting an extension of clock-stop to respond to the list of questions adopted in September 2020.

Action: For adoption

List of questions adopted on 17.09.2020.

3.4.3. covid-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735

Active immunization against COVID-19 disease.

Scope: Update on procedure

Action: For information

See also 15.1

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. autologous human chondrocytes *in vitro* expanded - ATMP - EMEA/H/C/004598

repair of cartilage defects of the knee joint.

Scope: Withdrawal of initial marketing authorisation application

Action: For information

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Sirturo - bedaquiline - Orphan - EMEA/H/C/002614/X/0036/G

Janssen-Cilag International NV

Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to add a new strength (20 mg tablets) grouped with a Type II variation (C.I.6) to extend the existing Sirturo indication to include paediatric patients aged from 5 years to less than 18 years of age and weighing more than 15 kg, based on the results of the week 24 analysis of Cohort 2 (paediatric subjects aged ≥5 to <12 years) of study TMC207-C211. Sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 and the product leaflet are

updated to support the extended indication. The RMP (version 4.4) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 17.09.2020. List of Questions adopted on 30.04.2020.

4.1.2. Xerava - eravacycline - EMEA/H/C/004237/X/0009

Tetraphase Pharmaceuticals Ireland Limited

Rapporteur: Filip Josephson, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension application to add a new strength of 100 mg for eravacycline powder for concentrate for solution for infusion. The RMP (version 3.0) is updated in accordance. Additionally, the marketing authorisation holder took the opportunity to align the PI with the latest QRD template."

Action: For adoption

List of Questions adopted on 17.09.2020.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Trimbow - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium - EMEA/H/C/004257/X/0012

Chiesi Farmaceutici S.p.A.

Rapporteur: Janet Koenig, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Jan Neuhauser

Scope: "Extension application to add a new pharmaceutical form (inhalation powder) associated with new strength (88 µg / 5 µg / 9 µg). The RMP (version 6.2) is updated in accordance."

Action: For adoption

List of Questions adopted on 23.07.2020.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Deltyba - delamanid - Orphan - EMEA/H/C/002552/X/0046/G

Otsuka Novel Products GmbH

Rapporteur: Christophe Focke, PRAC Rapporteur: Laurence de Fays

Scope: "Extension application to introduce a new pharmaceutical form (dispersible tablets) associated with a new strength (25 mg), grouped with a Type II extension of indication variation (C.I.6.a) to include the treatment of children of at least 10 kg of body weight for

the approved Deltyba 50 mg film-coated tablets. As a consequence, sections 3, 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet and labelling are updated accordingly. Version 3.3 of the RMP has also been submitted and Annex II is updated to remove the specific obligation related to an in vitro study using the HFS-TB model."

Action: For adoption

4.3.2. Insulin aspart Sanofi - insulin aspart - EMEA/H/C/005033/X/0003

sanofi-aventis groupe

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Annika Folin

Scope: "Extension application to introduce a new route of administration, intravenous use, for the 10 ml vial presentations only."

Action: For adoption

4.3.3. Skyrizi - risankizumab - EMEA/H/C/004759/X/0012

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Peter Kiely, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to add a new strength of 150 mg for solution for injection in a pre-filled syringe and pre-filled pen."

Action: For adoption

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.4.1. Diacomit - stiripentol - EMEA/H/C/000664/X/0032

BIOCODEX

Rapporteur: Alar Irs, PRAC Rapporteur: Maia Uusküla

Scope: "Extension application to add a new strength of 100 mg capsules. The RMP (version 2.0) is updated in accordance.",

Letter from the applicant dated 26 November 2020 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in November 2020.

Action: For adoption

List of Outstanding Issues adopted on 12.11.2020. List of Questions adopted on 25.06.2020.

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Bavencio - avelumab - EMEA/H/C/004338/II/0018

Merck Europe B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Hans Christian Siersted

Scope: "Extension of indication to include a new indication for Bavencio in the treatment as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 2.3 of the RMP has also been submitted. The marketing authorisation holder took also the occasion to include some editorial changes in the PI.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 17.09.2020.

5.1.2. Cabometyx - cabozantinib - EMEA/H/C/004163/II/0017

Ipsen Pharma

Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include in combination with nivolumab first line treatment of advanced renal cell carcinoma for Cabometyx. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 5.0 of the RMP has also been submitted."

Action: For adoption

5.1.3. Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0011

Sanofi Pasteur

Rapporteur: Christophe Focke

Scope: "To modify the approved therapeutic indication to include conditions for the eligibility to pre-vaccination serostatus screening. As a consequence, sections 4.1, 4.2 and 4.4 of the SmPC and sections 1, 2 and 3 of the package leaflet are updated accordingly."

Action: For adoption

5.1.4. Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0012

Sanofi Pasteur

Rapporteur: Christophe Focke

Scope: "Extension of indication to include paediatric population from 6 years of age for Dengvaxia. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC and sections 1, 2 and 4 of the package leaflet are updated. Furthermore, the marketing authorisation holder takes the opportunity to add an instruction for the installation of the needle in the SmPC and the package leaflet of the single-dose presentation."

Action: For adoption

5.1.5. Doptelet - avatrombopag - EMEA/H/C/004722/II/0004/G

Swedish Orphan Biovitrum AB (publ)

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to include the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. Consequently, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. Additionally, the SmPC section 5.3 is updated with data from juvenile toxicity studies. Furthermore, an additional pack size has been introduced with subsequent updates of sections 6.5 and 8.0 of the SmPC. The package leaflet and labelling are updated in accordance. Version 2.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.1."

Action: For adoption

Request for Supplementary Information adopted on 12.11.2020, 17.09.2020, 28.05.2020.

5.1.6. Evotaz - atazanavir / cobicistat - EMEA/H/C/003904/II/0038

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Bruno Sepodes, PRAC Rapporteur: Adrien Inoubli

Scope: "Extension of indication to include the use of Evotaz in combination with other antiretroviral agents in the treatment of HIV-1 infection in adolescent patients aged ≥ 12 to < 18 years, weighing ≥ 35 kg without known mutations associated with resistance to atazanavir. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the marketing authorisation holder took the opportunity to make minor editorial corrections."

Action: For adoption

5.1.7. Kaftrio - ivacaftor / tezacaftor / elexacaftor - Orphan - EMEA/H/C/005269/II/0001

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication of Kaftrio to patients with CF aged 12 years and older who have at least one F508del mutation in the CFTR gene, regardless of the second allele (F/any). Efficacy data are summarised from Study 104, which was conducted in subjects heterozygous for F508del and a gating (G) or residual function (RF) mutation (F/G and F/RF genotypes). As a consequence, update of SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 are requested. Package leaflet is updated accordingly. The RMP is updated version 1.1."

Action: For adoption

5.1.8. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0089

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension of indication to extend the indication of Kalydeco (ivacaftor) tablets in combination regimen with Kaftrio (ivacaftor/tezacaftor/elexacaftor) tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene. As a consequence, sections 4.1, 5.1, and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 9.2 of the RMP has also been submitted."

Action: For adoption

5.1.9. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0090

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of the currently approved therapeutic indication for the treatment of relapsed or refractory classical Hodgkin lymphoma (rrcHL) in adults to an earlier line of therapy and to include paediatric patients - as follows: Keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) following at least one prior therapy when ASCT is not a treatment option. The indication is based on the study KEYNOTE-204, a randomised, open-label, Phase 3 trial evaluating Keytruda monotherapy versus Brentuximab Vedotin (BV) for the treatment of patients with rrcHL and supportive data from updated analysis of KEYNOTE-087, which was the pivotal study supporting the initial rrcHL indication."

Action: For adoption

Request for Supplementary Information adopted on 17.09.2020.

5.1.10. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0091

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur:

Menno van der Elst

Scope: "C.I.6 -Extension of indication to include first-line treatment of unresectable or metastatic microsatellite instability-high (MSI H) or mismatch repair deficient (dMMR) colorectal cancer in adults for Keytruda based on the results from KEYNOTE-177 (an international, randomised, open-label Phase 3 trial of pembrolizumab versus chemotherapy in MSI-H or dMMR Stage IV Colorectal Carcinoma). As a consequence, sections 4.1, 4.2, and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. In addition, a minor correction has been made in section 4.4, 'Immune related endocrinopathies' subsection. Version 29.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 15.10.2020.

5.1.11. Libtayo - cemiplimab - EMEA/H/C/004844/II/0011

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Libtayo as monotherapy indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumor cells), with no EGFR, ALK or ROS1 aberrations, who have:
- locally advanced NSCLC and who are not candidates for surgical resection or definitive chemoradiation, or have progressed after treatment with definitive chemoradiation, or
- metastatic NSCLC.
The package leaflet is revised accordingly. A revised RMP is submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

5.1.12. Libtayo - cemiplimab - EMEA/H/C/004844/II/0012

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include: Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor. SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 have been revised. The package leaflet has been updated accordingly. A revised RMP has been submitted."

Action: For adoption

5.1.13. Nordimet - methotrexate - EMEA/H/C/003983/II/0016

Nordic Group B.V.

Rapporteur: Bruno Sepodes, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include the treatment of mild to moderate Crohn's

disease either alone or in combination with corticosteroids in patients refractory or intolerant to thiopurines for Nordimet. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. The RMP version 5.0 has also been submitted. The marketing authorisation holder took the opportunity to update the RMP with changes related to GVP V version 2 template and the outcome of MTX referral."

Action: For adoption

Request for Supplementary Information adopted on 17.09.2020, 30.04.2020.

5.1.14. Nplate - romiplostim - EMEA/H/C/000942/II/0077

Amgen Europe B.V.

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to add the use of romiplostim in adult patients who have had ITP for ≤ 12 months and who have had an insufficient response to corticosteroids or immunoglobulins. Sections 4.1, 4.4., 4.8, 5.1 and 5.2 of the SmPC have been updated. In addition, the marketing authorisation holder has taken the opportunity to implement minor editorial changes in sections 4.2, 4.4, 4.8 and 5.1 of the SmPC. Furthermore, the PI is being brought in line with the latest QRD template (version 10.1). The package leaflet has been updated accordingly. The updated RMP version 20.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 17.09.2020.

5.1.15. Opdivo - nivolumab - EMEA/H/C/003985/II/0092

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include in combination with cabozantinib for the first line treatment of advanced renal cell carcinoma for Opdivo. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 19.0 of the RMP has also been submitted."

Action: For adoption

5.1.16. Rinvoq - upadacitinib - EMEA/H/C/004760/II/0004

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "C.I.6 Extension of indication to include the treatment of active psoriatic arthritis in adult patients for Rinvoq. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Minor updates were made to the Annex II. Version 2.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 17.09.2020.

5.1.17. Rinvoq - upadacitinib - EMEA/H/C/004760/II/0005

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "C.I.6 Extension of indication to include the treatment of active ankylosing spondylitis in adult patient for Rinvoq. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Minor editorial changes to the SmPC and Annex II are also proposed. Version 3.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 17.09.2020.

5.1.18. Sarclisa - isatuximab - Orphan - EMEA/H/C/004977/II/0003

sanofi-aventis groupe

Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Eva A. Segovia

Scope: "An extension of indication for Sarclisa to add combination with carfilzomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. As a consequence, the sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 have been updated. The package leaflet is updated accordingly. The marketing authorisation holder took the opportunity to introduce minor changes in the SmPC sections 4.9, 6.3 and 6.6 and update the details of local representatives. Revised RMP version 1 has been submitted."

Action: For adoption

5.1.19. Spravato - esketamine - EMEA/H/C/004535/II/0001/G

Janssen-Cilag International N.V.

Rapporteur: Martina Weise, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kirsti Villikka

Scope: "C.I.6(a): Extension of indication to include a new indication for Spravato for the rapid reduction of depressive symptoms in adult patients with a moderate to severe depressive episode of MDD who have current suicidal ideation with intent.
As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 the SmPC are updated. The RMP version 2.1 has also been submitted.
B.II.e.5.a.2: addition of a new pack size corresponding to 4 weeks of treatment in the new indication. The package leaflet and labelling are updated in accordance. In addition, the marketing authorisation holder took the opportunity to clarify the wording in Annex II.D."

Action: For adoption

Request for Supplementary Information adopted on 15.10.2020, 30.04.2020.

5.1.20. Tagrisso - osimertinib - EMEA/H/C/004124/II/0039/G

AstraZeneca AB

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication of Tagrisso to include the adjuvant treatment after complete tumour resection in EGFR mutant non-small cell lung cancer (NSCLC) patients, based on the results from the pivotal Phase 3 randomised, placebo-controlled study ADAURA (D5164C00001). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.3 of the SmPC are updated. The package leaflet is updated accordingly. Version 14.1 of the RMP has also been submitted."

Action: For adoption

5.1.21. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0042

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include, in combination with platinum-based chemotherapy, first-line treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) for Tecentriq. As a consequence, sections 4.1, 4.2, 4.4 and 5.1 of the SmPC are updated. Version 14.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.06.2020.

5.1.22. WS1769
Iscover - clopidogrel - EMEA/H/C/000175/WS1769/0140
Plavix - clopidogrel - EMEA/H/C/000174/WS1769/0138

sanofi-aventis groupe

Lead Rapporteur: Bruno Sepodes, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include adult patients with high risk Transient Ischemic Attack (TIA) (ABCD2 score ≥4) or minor Ischemic Stroke (IS) (NIHSS ≤3) within 24 hours of either the TIA or IS event. The new indication is based on the results of two double-blind, randomised, placebo-controlled phase III trials (studies POINT & CHANCE). As a consequence, sections 4.1, 4.2, 4.4 and 5.1 of the SmPC are updated, the package leaflet is updated accordingly. Version 1.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 17.09.2020, 30.04.2020.

5.1.23. WS1881
Opdivo - nivolumab - EMEA/H/C/003985/WS1881/0091
Yervoy - ipilimumab - EMEA/H/C/002213/WS1881/0085

Bristol-Myers Squibb Pharma EEIG

Lead Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) for Opdivo in combination with Yervoy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 20.0 for Opdivo and version 30.0 for Yervoy of the RMP has also been submitted."

Action: For adoption

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

6.2. Update of Ancillary medicinal substances in medical devices

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. amivantamab - H0005454

indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Scope: Briefing note and the rapporteurs' recommendation on the request for accelerated assessment

Action: For adoption

8.2. Priority Medicines (PRIME)

Disclosure of information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0013

Sanofi Pasteur

Rapporteur: Christophe Focke

Scope: "To update sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a new posology regimen from 3 doses to 2 doses for individuals from 9 years of age based on interim results from study CYD65 listed as a category 3 study in the RMP. This is a Phase II, observer-blind, placebo-controlled trial in order to assess immunogenicity and safety of tetravalent dengue vaccine given in 1-, 2-, or 3-dose schedules followed by a single booster; section 3 of the package leaflet is updated accordingly."

Action: For adoption

9.1.2. Halimatoz - adalimumab - EMEA/H/C/04866

Sandoz GmbH

Rapporteur: Milena Stain, Co-Rapporteur: Peter Kiely

Scope: Withdrawal of marketing authorisation

Action: For information

9.1.3. Hexaxim - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inactivated) and haemophilus influenzae type b conjugate vaccine (adsorbed) - EMEA/H/W/002495

Sanofi Pasteur

Rapporteur: Jan Mueller-Berghaus

Scope: Stop of the maintenance of the scientific opinion under Article 58 of Hexaxim, suspension for injection

Action: For information

9.1.4. Prepandrix - split influenza virus inactivated - EMEA/H/C/0822

GlaxoSmithkline Biologicals SA

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Jan Mueller-Berghaus

Scope: Withdrawal of marketing authorisation

Action: For information

9.1.5. Remsima - infliximab - EMEA/H/C/002576/II/0095

Celltrion Healthcare Hungary Kft.

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Addition of a new posology for the rheumatoid arthritis indication that does not include IV induction doses."

Action: For adoption

9.1.6. Truberzi – eluxadoline - EMEA/H/C/4098

Allergan Pharmaceuticals International Limited

Rapporteur: Martina Weise, Co-Rapporteur: Johann Lodewijk Hillege

Scope: Withdrawal of marketing authorisation

Action: For information

9.1.7. Veklury - remdesivir - EMEA/H/C/005622/II/0012

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, Co-Rapporteur: Filip Josephson

Scope: "Submission of the final D28 mortality data by ordinal scale categories of study COUS-540-5776 (NIAID-ACTT1), listed as a specific obligation in the Annex II of the product information, in order to confirm the efficacy and safety of remdesivir in patients on invasive mechanical ventilation and extracorporeal membrane oxygenation (IMV/ECMO). In addition, the marketing authorisation holder discuss the potential imbalance in the use of corticosteroids and effect modification in study CO-US-540-5776. As a consequence, Annex II is updated accordingly."

Action: For adoption

Request for supplementary information adopted on 12.11.2020.

9.1.8. WS1844 - Forxiga/Edistride (dapagliflozin) – EMEA/H/C/002322 / EMEA/H/C/004161/WS1844

Astra Zeneca AB

Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin

Scope: "Re-categorisation of the Forxiga/Edistride PASS (D169C00011): Retrospective Cohort Study on the Risk of Diabetic Ketoacidosis (DKA) to determine the effectiveness of additional risk minimisation measures in place for DKA by assessing the impact of the risk minimisation measures on the risk of DKA in T1DM patients who are treated with dapagliflozin in Europe, from a category 1 to category 3 PASS in the RMP Version 20 and removal of the following Annex IID of the PI: Obligation to conduct the following Non-interventional PASS: In order to estimate the incidence of DKA in T1DM dapagliflozin users following implementation of RMMs in Europe, the MAH should conduct and submit the results from an observational cohort study using existing data sources in European countries where dapagliflozin will be launched for T1DM",

Oral explanation

Action: For adoption

Request for Supplementary Information adopted on 15.10.2020, 23.07.2020.

See 2.3

9.1.9. Xeljanz - tofacitinib - EMEA/H/C/004214/II/0027

Pfizer Europe MA EEIG

Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Update of sections 4.1, 4.2, 4.4 , 4.8, 5.1 and 5.2 of Xeljanz 11 mg prolonged-release tablets SmPC in order to include the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug therapy. As an alternative to the immediate release film-coated tablets section 4.2 of Xeljanz film-coated tablets is also updated to include

switching with the prolonged-release tablet in the treatment of PsA. The package leaflet is updated accordingly. The RMP version 13.1 has also been submitted."

Action: For adoption

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

10.5.1. Varilrix - EMEA/H/A-30/1499

MAH: GlaxoSmithKline Biologicals

Referral Rapporteur: Jan Mueller-Berghaus, Referral Co-Rapporteur: Sol Ruiz

Scope: List of Outstanding Issues

Action: For adoption

Harmonisation exercise for Varilrix and associated names. Product information harmonisation was triggered by the MAH.

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

December 2020 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

No items

14.2. Coordination with EMA Scientific Committees

14.2.1. Paediatric Committee (PDCO)

PIPs reaching D30 at December 2020 PDCO

Action: For information

Report from the PDCO meeting held on 8-11 December 2020

Action: For information

14.2.2. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 23-26 November 2020

Action: For information

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for December 2020

Action: For adoption

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP December 2020 meeting to CHMP for adoption:

- 13 reports on products in scientific advice and protocol assistance
- 15 reports on products in pre-authorisation procedures
- 3 reports on products in plasma master file

Action: For adoption

14.3.2. Infectious disease working party (IDWP)

Product information update across all medicinal products with indication in human immunodeficiency virus (HIV) – proposal

Action: For discussion

14.3.3. Name Review Group (NRG)

Adoption of November 2020 NRG ad-hoc ToD and overview of accepted names to date

Action: For adoption

Name request for a thalidomide-containing product initially submitted as an invented name

Action: For information

14.3.4. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 23-26 November 2020. Table of conclusions

Action: For information

Scientific advice letters:

Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.4. Cooperation within the EU regulatory network

14.4.1. Nitrosamines Multidisciplinary Expert Group (NMEG) on metformin

List of participants for the Nitrosamines Multidisciplinary Expert Group on metformin scheduled on 01 December 2020 adopted via written procedure on 27 November 2020

Action: For information

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

14.8.1. Update of the Business Pipeline report for the human scientific committees

Q4/2020 initial marketing authorisation application submissions with eligibility request to central procedure

Action: For information

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. New Executive Director at the EMA

Introduction of the new EMA Executive Director - Emer Cooke

15.1.2. Update on COVID-19

Action: For information

15.1.3. COVID-19 Vaccine (recombinant) - H0005737

prevention of coronavirus disease-2019 (COVID-19).

Scope: Rolling review timetable adopted via written procedure on 30.11.2020

Action: For information

15.1.4. COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735

Active immunization against COVID-19 disease.

Scope: Conditional marketing authorisation application timetable adopted at the ORGAM meeting on 30.11.2020

Action: For information

See also 3.4

15.1.5. COVID-19 mRNA vaccine - EMEA/H/C/005791

indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus in adults aged 18 years and older.

Scope: Conditional marketing authorisation application timetable adopted at the ORGAM meeting on 30.11.2020

Action: For information

16. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths,

formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a

particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

07 December 2020
EMA/CHMP/661750/2020

Annex to 07-10 December 2020 CHMP Agenda

Pre-submission and post-authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for December 2020: **For adoption**

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for December 2020: **For adoption**

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Brineura - cerliponase alfa - EMEA/H/C/004065/S/0028, Orphan
BioMarin International Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Ulla Wändel Liminga
Request for Supplementary Information adopted on 12.11.2020.

Increlex - mecasermin - EMEA/H/C/000704/S/0064
Ipsen Pharma, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka

Lojuxta - lomitapide - EMEA/H/C/002578/S/0043
Amryt Pharmaceuticals DAC, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst

Mepsevii - vestronidase alfa - EMEA/H/C/004438/S/0017, Orphan

Ultragenyx Germany GmbH, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Eva A. Segovia
Request for Supplementary Information adopted on 12.11.2020.

Strensiq - asfotase alfa - EMEA/H/C/003794/S/0048, Orphan
Alexion Europe SAS, Rapporteur: Armando Genazzani, PRAC Rapporteur: Rhea Fitzgerald

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

Neparvis - sacubitril / valsartan - EMEA/H/C/004343/R/0032
Novartis Europharm Limited, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Anette Kirstine Stark

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Alprolix - eftrenonacog alfa - EMEA/H/C/004142/R/0032, Orphan
Swedish Orphan Biovitrum AB (publ), Rapporteur: Andrea Laslop, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Brigitte Keller-Stanislawski
Request for Supplementary Information adopted on 15.10.2020.

EndolucinBeta - lutetium (177Lu) chloride - EMEA/H/C/003999/R/0019
ITM Medical Isotopes GmbH, Rapporteur: Peter Kiely, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Rugile Pilviniene

Flixabi - infliximab - EMEA/H/C/004020/R/0064
Samsung Bioepis NL B.V., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Ulla Wändel Liminga
Request for Supplementary Information adopted on 12.11.2020.

Galafold - migalastat - EMEA/H/C/004059/R/0027, Orphan
Amicus Therapeutics Europe Limited, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur:

Ulla Wändel Liminga
Request for Supplementary Information adopted on 12.11.2020.

IDELVION - albutrepenonacog alfa - EMEA/H/C/003955/R/0047, Orphan
CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Menno van der Elst
Request for Supplementary Information adopted on 12.11.2020.

Ongentys - opicapone - EMEA/H/C/002790/R/0031
Bial - Portela & Cª, S.A., Rapporteur: Martina Weise, Co-Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Maria del Pilar Rayon

Palonosetron Accord - palonosetron - EMEA/H/C/004129/R/0009
Accord Healthcare S.L.U., Generic, Generic of Aloxi, Rapporteur: Alar Irs, PRAC Rapporteur: Rhea Fitzgerald

Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - EMEA/H/C/003854/R/0029, Orphan, ATMP
Orchard Therapeutics (Netherlands) BV, Rapporteur: Sol Ruiz, Co-Rapporteur: Egbert Flory, PRAC Rapporteur: Menno van der Elst

Zavicefta - ceftazidime / avibactam - EMEA/H/C/004027/R/0024
Pfizer Ireland Pharmaceuticals, Rapporteur: Bjorg Bolstad, Co-Rapporteur: Simona Stankeviciute, PRAC Rapporteur: Rugile Pilviniene

B.2.3. Renewals of Conditional Marketing Authorisations

Bosulif - bosutinib - EMEA/H/C/002373/R/0045
Pfizer Europe MA EEIG, Rapporteur: Janet Koenig, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Martin Huber

Cometriq - cabozantinib - EMEA/H/C/002640/R/0042, Orphan
Ipsen Pharma, Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Bjorg Bolstad,

PRAC Rapporteur: Menno van der Elst

Deltyba - delamanid -
EMEA/H/C/002552/R/0047, Orphan
Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, PRAC Rapporteur: Laurence de Fays

Natpar - parathyroid hormone -
EMEA/H/C/003861/R/0027, Orphan
Shire Pharmaceuticals Ireland Limited, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Rhea Fitzgerald

Ondexxya - andexanet alfa -
EMEA/H/C/004108/R/0015
Portola Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Menno van der Elst

WAYLIVRA - volanesorsen -
EMEA/H/C/004538/R/0009, Orphan
Akcea Therapeutics Ireland Limited, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Martin Huber

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

SIGNAL DETECTION

PRAC recommendations on signals adopted at the PRAC meeting held on 23-26 November 2020:

Signal of anaphylactic reaction

Xeloda, Capecitabine Accord, Capecitabine Medac, Capecitabine Teva, Ecansya - capecitabine, Rapporteur: various, Co-Rapporteur: various,
Scope: PRAC recommendation on a variation
Action: For adoption

Signal of vasculitis

Keytruda - pembrolizumab, Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, ,
Scope: PRAC recommendation on a variation
Action: For adoption

PSUR PROCEDURES

PRAC recommendation for variation of the terms of the MA at the PRAC meeting held on 23-26 November 2020:

EMEA/H/C/PSUSA/00000424/202004
(bortezomib)
CAPS:
Bortezomib Accord (EMEA/H/C/003984) (bortezomib), Accord Healthcare S.L.U., Rapporteur: Milena Stain
Bortezomib Fresenius Kabi (EMEA/H/C/005074) (bortezomib), Fresenius Kabi Deutschland GmbH, Rapporteur: Kolbeinn Gudmundsson
Bortezomib Hospira (EMEA/H/C/004207) (bortezomib), Pfizer Europe MA EEIG, Rapporteur: Milena Stain
Bortezomib SUN (EMEA/H/C/004076) (bortezomib), Sun Pharmaceutical Industries Europe B.V., Rapporteur: Margareta Bego
VELCADE (EMEA/H/C/000539) (bortezomib), Janssen-Cilag International NV, Rapporteur: Armando Genazzani
NAPS:
NAPs - EUR
PRAC Rapporteur: Amelia Cupelli, "26/04/2019 To: 25/04/2020"

EMEA/H/C/PSUSA/00002772/202003
(somatropin)
CAPS:
NutropinAq (EMEA/H/C/000315) (somatropin), Ipsen Pharma, Rapporteur: Kirstine Moll Harboe
Omnitrope (EMEA/H/C/000607) (somatropin), Sandoz GmbH, Rapporteur: Johann Lodewijk Hillege
NAPS:
NAP - EU
PRAC Rapporteur: Anette Kirstine Stark, "Period covered by the PSUR: 31/03/2017 To: 31/03/2020"

EMEA/H/C/PSUSA/00010044/202004
(meningococcal group A, C, W135, Y conjugate vaccines (conjugated to tetanus toxoid carrier protein))
CAPS:
Nimenrix (EMEA/H/C/002226) (meningococcal group A, C, W135 and Y conjugate vaccine), Pfizer Europe MA EEIG, Rapporteur: Bjorg Bolstad, PRAC Rapporteur: David Olsen,

"20/04/2019 To: 19/04/2020"	
EMEA/H/C/PSUSA/00010550/202005 (mycophenolate mofetil, mycophenolic acid) CAPS: **CellCept** (EMEA/H/C/000082) (mycophenolate mofetil), Roche Registration GmbH, Rapporteur: Kirstine Moll Harboe **Myclausen** (EMEA/H/C/001218) (mycophenolate mofetil), Passauer Pharma GmbH, Rapporteur: Andrea Laslop **Mycophenolate mofetil Teva** (EMEA/H/C/000882) (mycophenolate mofetil), Teva B.V., Rapporteur: Ondřej Slanař **Myfenax** (EMEA/H/C/000884) (mycophenolate mofetil), Teva B.V., Rapporteur: Ondřej Slanař NAPS: **NAPs** - EU PRAC Rapporteur: Hans Christian Siersted, "03/05/2019 To: 02/05/2020"	

B.4. EPARs / WPARs

ELZONRIS - tagraxofusp - EMEA/H/C/005031, Orphan Stemline Therapeutics B.V., treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Gamifant - emapalumab - EMEA/H/C/004386, Orphan Swedish Orphan Biovitrum AB (publ), treatment of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH)., New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Onbevzi - bevacizumab - EMEA/H/C/005640 Samsung Bioepis NL B.V., treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix, Similar biological application (Article 10(4) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Phesgo - pertuzumab / trastuzumab - EMEA/H/C/005386 Roche Registration GmbH, treatment of early breast cancer, metastatic breast cancer, Fixed	For information only. Comments can be sent to the PL in case necessary.

combination application (Article 10b of Directive No 2001/83/EC)	
Roclanda - latanoprost / netarsudil - EMEA/H/C/005107 Aerie Pharmaceuticals Ireland Limited, reduction of elevated intraocular pressure, Fixed combination application (Article 10b of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Xofluza - baloxavir marboxil - EMEA/H/C/004974 Roche Registration GmbH, Treatment of influenza in patients aged 12 and above, including patients at high risk of developing influenza-related complications and for post-exposure prophylaxis of influenza in individuals aged 12, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0013 Baxalta Innovations GmbH, Rapporteur: Andrea Laslop Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 23.07.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
AMGEVITA - adalimumab - EMEA/H/C/004212/II/0023 Amgen Europe B.V., Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 19.11.2020.	Request for supplementary information adopted with a specific timetable.
Beovu - brolucizumab - EMEA/H/C/004913/II/0005/G Novartis Europharm Limited, Rapporteur: Alexandre Moreau	
Beromun - tasonermin - EMEA/H/C/000206/II/0050 Belpharma s.a., Rapporteur: Sinan B. Sarac	
Beromun - tasonermin - EMEA/H/C/000206/II/0051	

Belpharma s.a., Rapporteur: Sinan B. Sarac	
Cerezyme - imiglucerase - EMEA/H/C/000157/II/0118 Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 19.11.2020.	Positive Opinion adopted by consensus on 19.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Cinqaero - reslizumab - EMEA/H/C/003912/II/0037/G Teva B.V., Rapporteur: Johann Lodewijk Hillege Opinion adopted on 19.11.2020.	Positive Opinion adopted by consensus on 19.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Cinryze - c1 esterase inhibitor (human) - EMEA/H/C/001207/II/0082/G Shire Services BVBA, Rapporteur: Jan Mueller-Berghaus	
Daptomycin Hospira - daptomycin - EMEA/H/C/004310/II/0014/G Pfizer Europe MA EEIG, Generic, Generic of Cubicin, Rapporteur: Kolbeinn Gudmundsson Request for Supplementary Information adopted on 17.09.2020.	
Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva - efavirenz / emtricitabine / tenofovir disoproxil - EMEA/H/C/004250/II/0019 Zentiva k.s., Generic, Generic of Atripla, Rapporteur: Tomas Radimersky Request for Supplementary Information adopted on 03.09.2020.	
Emtricitabine/Tenofovir disoproxil Zentiva - emtricitabine / tenofovir disoproxil - EMEA/H/C/004137/II/0015 Zentiva k.s., Generic, Generic of Truvada, Rapporteur: Alar Irs Request for Supplementary Information adopted on 03.09.2020, 28.05.2020.	
Eylea - aflibercept - EMEA/H/C/002392/II/0062/G Bayer AG, Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 10.09.2020.	
Herzuma - trastuzumab - EMEA/H/C/002575/II/0032/G Celltrion Healthcare Hungary Kft., Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 01.10.2020.	

Hulio - adalimumab - EMEA/H/C/004429/II/0021 Mylan S.A.S, Rapporteur: Christophe Focke	
IDELVION - albutrepenonacog alfa - EMEA/H/C/003955/II/0041/G, Orphan CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 15.10.2020, 16.07.2020.	
IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/II/0050 Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 19.11.2020. Request for Supplementary Information adopted on 03.09.2020.	Positive Opinion adopted by consensus on 19.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/II/0055 Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 08.10.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Invokana - canagliflozin - EMEA/H/C/002649/II/0052/G Janssen-Cilag International NV, Rapporteur: Martina Weise Request for Supplementary Information adopted on 17.09.2020.	
Kentera - oxybutynin - EMEA/H/C/000532/II/0059 Teva B.V., Rapporteur: Karin Janssen van Doorn Request for Supplementary Information adopted on 26.11.2020.	Request for supplementary information adopted with a specific timetable.
Kyprolis - carfilzomib - EMEA/H/C/003790/II/0050/G, Orphan Amgen Europe B.V., Rapporteur: Blanca Garcia-Ochoa	
Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0060 Teva B.V., Rapporteur: Outi Mäki-Ikola	
Lyumjev - insulin lispro - EMEA/H/C/005037/II/0006/G Eli Lilly Nederland B.V., Rapporteur: Outi Mäki-	Request for supplementary information adopted with a specific timetable.

Ikola"B.IV.z (Type II) - To introduce an additional pre-filled pen presentation
B.II.e.5.a.1 (Type IAIN) - To introduce an additional pre-filled pen presentation
As a consequence, sections 1, 2, 4.2, 4.4, 6.4, 6.5, 6.6 and 8 of the SmPC were updated in order to add the new pre-filled pen presentations; the Package Leaflet and Labelling are updated accordingly. Furthermore, the MAH took the opportunity to introduce editorial changes in the product information and Annex A."
Request for Supplementary Information adopted on 26.11.2020.

M-M-RVAXPRO - measles, mumps and rubella vaccine (live) - EMEA/H/C/000604/II/0103
MSD Vaccins, Rapporteur: Jan Mueller-Berghaus

Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0042
Orexigen Therapeutics Ireland Limited, Rapporteur: Kirstine Moll Harboe
Request for Supplementary Information adopted on 23.07.2020.

Nulojix - belatacept - EMEA/H/C/002098/II/0071
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson
Request for Supplementary Information adopted on 15.10.2020.

Nulojix - belatacept - EMEA/H/C/002098/II/0072/G
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson
Request for Supplementary Information adopted on 22.10.2020.

Palynziq - pegvaliase - EMEA/H/C/004744/II/0014, Orphan
BioMarin International Limited, Rapporteur: Johann Lodewijk Hillege

Pemetrexed Sandoz - pemetrexed - EMEA/H/C/004011/II/0009
Sandoz GmbH, Generic, Generic of Alimta, Rapporteur: Bjorg Bolstad

Privigen - human normal immunoglobulin - EMEA/H/C/000831/II/0169

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus	
ProQuad - measles, mumps, rubella and varicella vaccine (live) - EMEA/H/C/000622/II/0143 MSD Vaccins, Rapporteur: Jan Mueller-Berghaus	
Puregon - follitropin beta - EMEA/H/C/000086/II/0111/G Merck Sharp & Dohme B.V., Rapporteur: Peter Kiely	
Puregon - follitropin beta - EMEA/H/C/000086/II/0112/G Merck Sharp & Dohme B.V., Rapporteur: Peter Kiely	
Reblozyl - luspatercept - EMEA/H/C/004444/II/0001/G, Orphan Celgene Europe BV, Rapporteur: Milena Stain Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 15.10.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Reblozyl - luspatercept - EMEA/H/C/004444/II/0002/G, Orphan Celgene Europe BV, Rapporteur: Milena Stain	
Riluzole Zentiva - riluzole - EMEA/H/C/002622/II/0027 Zentiva, k.s., Rapporteur: Kirstine Moll Harboe Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 24.09.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Sancuso - granisetron - EMEA/H/C/002296/II/0058 Kyowa Kirin Holdings B.V., Rapporteur: Simona Stankeviciute Request for Supplementary Information adopted on 12.11.2020, 03.09.2020.	
Simulect - basiliximab - EMEA/H/C/000207/II/0107 Novartis Europharm Limited, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 15.10.2020.	
Spectrila - asparaginase - EMEA/H/C/002661/II/0021/G medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Andrea Laslop	

Strensiq - asfotase alfa - EMEA/H/C/003794/II/0050, Orphan Alexion Europe SAS, Rapporteur: Armando Genazzani Request for Supplementary Information adopted on 19.11.2020.	Request for supplementary information adopted with a specific timetable.
Thyrogen - thyrotropin alfa - EMEA/H/C/000220/II/0106 Genzyme Europe BV, Rapporteur: Peter Kiely Opinion adopted on 19.11.2020.	Positive Opinion adopted by consensus on 19.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Trulicity - dulaglutide - EMEA/H/C/002825/II/0054 Eli Lilly Nederland B.V., Rapporteur: Martina Weise Request for Supplementary Information adopted on 29.10.2020.	
Voncento - human coagulation factor VIII / human von Willebrand factor - EMEA/H/C/002493/II/0045 CSL Behring GmbH, Rapporteur: Paula Boudewina van Hennik	
Xadago - safinamide - EMEA/H/C/002396/II/0034 Zambon S.p.A., Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 26.11.2020, 02.04.2020, 16.01.2020.	Request for supplementary information adopted with a specific timetable.
Xolair - omalizumab - EMEA/H/C/000606/II/0105/G Novartis Europharm Limited, Rapporteur: Kristina Dunder	
Yervoy - ipilimumab - EMEA/H/C/002213/II/0086 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik	
Zavicefta - ceftazidime / avibactam - EMEA/H/C/004027/II/0023/G Pfizer Ireland Pharmaceuticals, Rapporteur: Bjorg Bolstad Request for Supplementary Information adopted on 06.11.2020, 01.10.2020.	
WS1906/G Hexacima-EMEA/H/C/002702/WS1906/	

0108/G **Hexaxim-EMEA/H/W/002495/WS1906/0113/G** **Hexyon-EMEA/H/C/002796/WS1906/0112/G** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus	
WS1914/G **Mircera-EMEA/H/C/000739/WS1914/0080/G** **NeoRecormon-EMEA/H/C/000116/WS1914/0109/G** Roche Registration GmbH, Lead Rapporteur: Martina Weise Opinion adopted on 19.11.2020.	Positive Opinion adopted by consensus on 19.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1924 **HyQvia-EMEA/H/C/002491/WS1924/0064** **Kiovig-EMEA/H/C/000628/WS1924/0105** Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 26.11.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1982 **Aflunov-EMEA/H/C/002094/WS1982/0065** **Foclivia-EMEA/H/C/001208/WS1982/0061** Seqirus S.r.l, Lead Rapporteur: Armando Genazzani	

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

AUBAGIO - teriflunomide - EMEA/H/C/002514/II/0033 sanofi-aventis groupe, Rapporteur: Martina Weise, "To update sections 4.4 and 4.8 of the SmPC regarding skin reactions in particular to drug reaction with eosinophilia and systemic symptoms (DRESS) and to update the frequency of severe skin reactions from "Not known" to "Uncommon", following a review of the Sanofi global PV database. The Package Leaflet section 4 is updated as to add fever." Request for Supplementary Information adopted on 19.11.2020.	Request for supplementary information adopted with a specific timetable.
Caelyx pegylated liposomal - doxorubicin - EMEA/H/C/000089/II/0094 Janssen-Cilag International NV, Rapporteur: Ondřej Slanař, "Update of sections 4.2 and 4.8	

of the SmPC in line with the SmPC guideline. In addition, the MAH took the opportunity to update the PI in line with the QRD template version 10.1 and with the EDQM standard terms. Furthermore, the list of local representatives in the Package Leaflet is updated." Request for Supplementary Information adopted on 03.09.2020, 14.05.2020.	
Darzalex - daratumumab - EMEA/H/C/004077/II/0041, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, "C.I.4 Update of section 4.8 of the SmPC in order to include CMV infections as a new adverse drug reaction (ADR) with frequency common following a comprehensive, cross-program evaluation of all potential cases of treatment-emergent cytomegalovirus (CMV) infections with use of daratumumab. The Package Leaflet is updated accordingly. Several minor linguistic improvements are also proposed."	
Dengvaxia - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171/II/0013 Sanofi Pasteur, Rapporteur: Christophe Focke, "To update sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a new posology regimen from 3 doses to 2 doses for individuals from 9 years of age based on interim results from study CYD65 listed as a category 3 study in the RMP; this is a Phase II, observer-blind, placebo-controlled trial in order to assess Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3-Dose Schedules Followed by a Single Booster; section 3 of the Package Leaflet is updated accordingly"	See agenda 9.1
Foclivia - influenza virus surface antigens (inactivated) of strain A/Vietnam/1194/2004 (H5N1) - EMEA/H/C/001208/II/0058 Seqirus S.r.l, Rapporteur: Armando Genazzani, "Update of sections 2, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 5.1, 6.4 and 6.5 of the SmPC based on data obtained from two clinical trials (V87_25 and V87_26) already assessed and approved for Aflunov, the corresponding H5N1 Zoonotic Influenza Vaccine (procedure EMEA/H/C/002094/II/0044/G approved in June	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

2019) in order to align both products. In addition, the MAH took the opportunity to also add in section 5.1 data from study V87P2 and study V87P11 (A/Turkey/turkey/1/2005) included for the RMP of both products and in the label of Aflunov for further alignment; the Package Leaflet and Labelling are updated accordingly. Finally, the Marketing authorization holder (MAH) makes additional changes based on the most recent EU Guidelines and some additional minor editorial corrections." Opinion adopted on 26.11.2020.	
Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042/II/0070/G Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, "- C.I.4 (Type II): Update of section 4.5 of the SmPC to include data on the drug-drug interaction between Genvoya and the thienopyridine anti-platelet drugs clopidogrel and prasugrel, based on a MAH cumulative safety review. The Package Leaflet is updated accordingly. - C.I.4 (Type II): Update of section 4.5 of the SmPC to include data on the drug-drug interaction between Genvoya and medicinal products or oral supplements containing polyvalent cations, based on a MAH cumulative safety review. The Package Leaflet is updated accordingly. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to correct the amount of lactose stated in section 2 of the SmPC and make minor editorial changes throughout the PI."	
Imfinzi - durvalumab - EMEA/H/C/004771/II/0024 AstraZeneca AB, Rapporteur: Sinan B. Sarac, "Update of sections 4.4 and 4.8 of the SmPC in order to add immune thrombocytopenia to the list of adverse drug reactions (ADRs) with frequency (rare) following the MAH internal review; the Package Leaflet (PL) is updated accordingly. The MAH took the opportunity to correct information in the PL and to make editorial changes to the names of the manufacturer in Annex II."	
Invanz - ertapenem -	Positive Opinion adopted by consensus on

EMEA/H/C/000389/II/0062 Merck Sharp & Dohme B.V., Rapporteur: Fátima Ventura, "Update of section 4.8 of the SmPC in order to add 'hypersensitivity vasculitis' to the list of adverse drug reactions (ADRs) with frequency 'Rare', based on post-marketing reports; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, update the PI in line with the Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (EMA/CHMP/302620/2017 Rev.1) regarding sodium content, and bring the PI in line with the latest QRD template version 10.1. The MAH also updated the Package leaflet to add the missing adverse event "injection site induration" with frequency 'Rare'." Opinion adopted on 03.12.2020.	03.12.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Jinarc - tolvaptan - EMEA/H/C/002788/II/0031 Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Armando Genazzani, "Update of sections 4.2 and 4.4 of the SmPC in order to include information on patients with CKD late stage 4 based on final results from study 156-12-211 listed as a category 3 study in the RMP; this is a Phase 3b, Multicenter, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC-41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease."	
Keytruda - pembrolizumab - EMEA/H/C/003820/II/0094 Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, "Update of sections 4.4 and 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-361 listed as a PAES in the Annex II; this is a Phase III Randomised, Controlled Clinical Trial of Pembrolizumab with or without Platinum-based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma; Annex IID is updated accordingly."	
Lorviqua - lorlatinib - EMEA/H/C/004646/II/0009/G	

Pfizer Europe MA EEIG, Rapporteur: Sinan B. Sarac, "Update of sections 4.2 and 5.2 of the SmPC in order to change the posology recommendations in patients with severe renal impairment based on the results from study B7461010 (a phase 1, single dose open-label study to evaluate the pharmacokinetics of lorlatinib in subjects with impaired renal function). The package leaflet has been updated accordingly. Update of sections 4.4 and 4.5 of the SmPC in order to include information regarding drug-drug interaction with moderate CYP3A4/5 inducers based on study B7461026 (Phase 1, open-label, fixed sequence, 2-period study to investigate the effect of multiple doses of modafinil on the pharmacokinetics of single dose lorlatinib in healthy participants). The MAH took the opportunity to update the list of local representatives in the Package Leaflet."	
LUTATHERA - lutetium (177Lu) oxodotreotide - EMEA/H/C/004123/II/0022, Orphan Advanced Accelerator Applications, Rapporteur: Janet Koenig, "Update of sections 4.2, 4.4, 4.5, 4.6 and 4.8 of the SmPC in order to introduce structural changes in the dosing and administration and warnings and precautions section, include clarifications in the pregnancy and overdose sections, update instructions for use based on end user feedback and update of amino acid solution information based on review and approval of LysaKare; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include correction of typographical errors and editorial changes in the PI in line with the latest QRD template version 10.1." Request for Supplementary Information adopted on 12.11.2020.	
Lyumjev - insulin lispro - EMEA/H/C/005037/II/0005 Eli Lilly Nederland B.V., Rapporteur: Outi Mäki-Ikola, "Update of sections 4.2 and 5.2 of the SmPC in order to update pharmacokinetic information based on final results from study I8B-MC-ITSA (submitted in accordance with Article 46 of regulation (EC) No 1901/2006). This study was conducted to evaluate the	

pharmacokinetics and glucodynamics of Lyumjev compared to Humalog in children, adolescents, and adults with Type 1 Diabetes Mellitus." Request for Supplementary Information adopted on 15.10.2020.	
Maviret - glecaprevir / pibrentasvir - EMEA/H/C/004430/II/0037 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Jean-Michel Race, "Submission of the final clinical study report from study B16-439 (Phase 3b, a Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy)." Request for Supplementary Information adopted on 19.11.2020.	Request for supplementary information adopted with a specific timetable.
Mekinist - trametinib - EMEA/H/C/002643/II/0041 Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.5, 4.6 and 5.2 of the SmPC in order to add drug-drug interaction information with hormonal contraceptives and to updated relevant part of the SmPC regarding this interaction; the Package Leaflet is updated accordingly. Furthermore the MAH took the occasion to include the information regarding the sodium content in the products in line with relevant guidelines and to bring the PI in line with the latest QRD template version 10.1. In addition, the MAH took the opportunity to introduce some editorial changes in the PI and to update the list of local representatives for The Netherlands in the Package Leaflet."	
NINLARO - ixazomib - EMEA/H/C/003844/II/0025, Orphan Takeda Pharma A/S, Rapporteur: Armando Genazzani, "Update of the SmPC section 4.9 with additional information on Ninlaro overdose. The Package leaflet is updated accordingly." Request for Supplementary Information adopted on 26.11.2020.	Request for supplementary information adopted with a specific timetable.
Nplate - romiplostim - EMEA/H/C/000942/II/0078 Amgen Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.8	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

and 5.1 of the SmPC to reflect the main results from study 20101221 following the assessment performed under Article 46 of Regulation 1901/2006. Study 20101221 is an open-label trial to evaluate safety in children from 1 year of age to less than 18 years of age with primary ITP regardless of splenectomy status, including a protocol supplement to implement bone marrow evaluations." Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 03.09.2020.	recommendation.
OFEV - nintedanib - EMEA/H/C/003821/II/0034 Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, "Update of section 5.1 of SmPC to include results of a double-blind, randomised, parallel-group trial to evaluate the efficacy and safety of Ofev co-administered with oral sildenafil, compared to treatment with Ofev alone (INSTAGE Trial)." Request for Supplementary Information adopted on 22.10.2020, 16.07.2020.	
Ozempic - semaglutide - EMEA/H/C/004174/II/0014 Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.2 and 5.1 of the SmPC in order to include information on the use of semaglutide once weekly in combination with a SGLT-2 inhibitor, based on the final results from the SUSTAIN 9 study (study NN9535-4269); this is a 30-week, randomised, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of semaglutide as add-on to treatment with an SGLT-2 inhibitor ± metformin or sulphonylurea (SU) in subjects with T2DM; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 10.09.2020, 05.06.2020.	
Palynziq - pegvaliase - EMEA/H/C/004744/II/0015, Orphan BioMarin International Limited, Rapporteur: Johann Lodewijk Hillege, "Submission of the final report from the non-clinical study BMN-165-18-080 listed as a category 3 study in the RMP."	
Parsabiv - etelcalcetide - EMEA/H/C/003995/II/0015	

Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Andrea Laslop (AT) (MNAT with AT for Coordination, AT for Clinical Efficacy, AT for Non-Clinical, AT for Clinical Pharmacology, AT for Clinical Safety, DE-BfArM for Quality), "Update of the SmPC section 4.4 to remove anti-etelcalcetide antibodies testing, and update of the Product information in line with QRD template v10.1."	
Perjeta - pertuzumab - EMEA/H/C/002547/II/0053 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Submission of the final report from study MO27775 (PERTAIN). This is a randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patients with HER2-positive and hormone receptor-positive advanced (metastatic or locally advanced) breast cancer." Opinion adopted on 19.11.2020.	Positive Opinion adopted by consensus on 19.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Qutenza - capsaicin - EMEA/H/C/000909/II/0051/G Grunenthal GmbH, Rapporteur: Bruno Sepodes, "Update of section 4.2 and 4.4 to delete the explicit reference to pre- treatments used in clinical trials and to opioids. Update of section 4.4 of the SmPC to include more detail on unintended exposure to capsaicin."	
Remsima - infliximab - EMEA/H/C/002576/II/0095 Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, "Addition of a new posology for the rheumatoid arthritis indication that does not include IV induction doses."	See agenda 9.1
Rubraca - rucaparib - EMEA/H/C/004272/II/0024/G Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, "Submission of the final reports from four non-clinical studies (Report 181000, OPT-2018-074, 8388100 and CLO-P8799)."	
Stelara - ustekinumab - EMEA/H/C/000958/II/0083 Janssen-Cilag International NV, Rapporteur: Jayne Crowe, "Update of section 4.8 of the	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

SmPC in order to add hypersensitivity vasculitis to the list of adverse drug reactions (ADRs) with frequency rare based on cumulative review from the literature and post-marketing reporting; the Package Leaflet is updated accordingly." Opinion adopted on 26.11.2020.	recommendation.
Stivarga - regorafenib - EMEA/H/C/002573/II/0031 Bayer AG, Rapporteur: Paula Boudewina van Hennik, "Submission of final study report for study 15982, a randomized, double blind, placebo-controlled, multicenter Phase 3 study that investigated regorafenib in subjects with hepatocellular carcinoma (HCC) after progression on sorafenib treatment." Request for Supplementary Information adopted on 26.11.2020.	Request for supplementary information adopted with a specific timetable.
Taltz - ixekizumab - EMEA/H/C/003943/II/0038/G Eli Lilly Nederland B.V., Rapporteur: Kristina Dunder, "Clinical studies in adult plaque psoriasis: Type II- C.I.4 -Update of section 5.1 of the SmPC regarding long term data in the treatment of psoriasis: RHAZ, RHBA, RHBC (3 studies of the "UNCOVER" series) were the pivotal registration studies, with response data up to 60 weeks already included in the SmPC. The current update relates to the extension data available, covering a total of 5 years. Section 5.1 of the SmPC has also been updated with information from study RHCR (known as "IXORA-R") which is a 24-week head-to-head comparison of Taltz vs guselkumab. Clinical studies in adult psoriatic arthritis: Type II- C.I.4 -Update of section 5.1 of the SmPC regarding long term data in the treatment of psoriatic arthritis: RHAP and RHBE (also known as SPIRIT-P1 and P2) were pivotal registration studies, with response data at 24 weeks and up to 52 weeks (SPIRIT-P1) already included in the SmPC. The current update relates to extension data available covering a total of 3 years. Section 5.1 of the SmPC has also been updated with longer-term data from study RHCF ("SPIRIT-H2H" Taltz vs adalimumab). Response data of up to 24 weeks are already in the SmPC and the addition of 52 week data are being proposed." Request for Supplementary Information adopted	

on 15.10.2020.	
Tecentriq - atezolizumab - EMEA/H/C/004143/II/0050 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Update of section 5.1 of the SmPC in order to reflect efficacy results based on the final OS analysis from study WO29522 (IMpassion130) comparing atezolizumab in combination with nab-paclitaxel with placebo with nab-paclitaxel for patients with previously untreated metastatic triple-negative breast cancer."	
Uptravi - selexipag - EMEA/H/C/003774/II/0029 Janssen-Cilag International N.V., Rapporteur: Martina Weise, "Update of section 5.1 of the SmPC based on interim survival and safety data from study AC-065A303 a long-term single-arm, open-label study to evaluate the safety and tolerability of selexipag / ACT-293987 in patients with Pulmonary Arterial Hypertension. In addition, the MAH took the opportunity to implement minor editorial changes and update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 03.09.2020.	
Veklury - remdesivir - EMEA/H/C/005622/II/0012 Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Submission of the final D28 mortality data by ordinal scale categories of Study COUS-540-5776 (NIAID-ACTT1), listed as a Specific Obligation in the Annex II of the Product Information, in order to confirm the efficacy and safety of remdesivir in patients on Invasive Mechanical Ventilation and Extracorporeal Membrane Oxygenation (IMV/ECMO). In addition, the MAH discuss the potential imbalance in the use of corticosteroids and effect modification in Study CO-US-540-5776. As a consequence, Annex II is updated accordingly." Request for Supplementary Information adopted on 12.11.2020.	See agenda 9.1
Vyxeos liposomal - daunorubicin / cytarabine - EMEA/H/C/004282/II/0014, Orphan Jazz Pharmaceuticals Ireland Limited,	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

Rapporteur: Johanna Lähteenvuo, "Update of section 5.1 of the SmPC to reflect the 5-years overall survival data from the Follow-Up Phase of the Phase 3 Study CPX310-301. Additionally, the MAH has introduced minor editorial changes in the PI." Opinion adopted on 26.11.2020.	recommendation.
XOSPATA - gilteritinib - EMEA/H/C/004752/II/0001, Orphan Astellas Pharma Europe B.V., Rapporteur: Bjorg Bolstad, "Submission of a pooled analysis report from studies 2215-CL-0101 (Phase 1/2), 2215-CL-0102 (Phase 1), 2215-CL-0301, 2215-CL-9100 (phase 3) listed as "Other forms of routine pharmacovigilance activities in section III.1 of the RMP". This is a pooled analysis to characterise gilteritinib-related differentiation syndrome, specifically incidence, observed signs and symptoms, duration, and response to intervention based on patient-level data from on-going trials in patients with acute myeloid leukaemia." Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 08.10.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
XOSPATA - gilteritinib - EMEA/H/C/004752/II/0003, Orphan Astellas Pharma Europe B.V., Rapporteur: Bjorg Bolstad, "C.I.4 Update of sections 4.4, 4.5 and 5.2 of the SmPC in order to update information about Transporter drug-drug interactions based on final results from in vitro transporter studies identified as recommendations by CHMP (REC003) during the initial approval. In addition, the MAH took the opportunity to perform minor corrections and editorial changes in the PI." Request for Supplementary Information adopted on 29.10.2020, 03.09.2020.	
Xtandi - enzalutamide - EMEA/H/C/002639/II/0050 Astellas Pharma Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 4.8 of the SmPC in order to add severe skin reactions to the list of adverse drug reactions (ADRs) with frequency not known based on a safety review; the Package Leaflet is updated accordingly. In addition, the MAH took the	Request for supplementary information adopted with a specific timetable.

opportunity to make minor corrections in the SmPC." Request for Supplementary Information adopted on 26.11.2020.	
Zerbaxa - ceftolozane / tazobactam - EMEA/H/C/003772/II/0032 Merck Sharp & Dohme B.V., Rapporteur: Bjorg Bolstad, "Update of section 5.1 of the SmPC for Zerbaxa to implement the EUCAST MIC breakpoints of ceftolozanetazobactam for Enterobacterales according to the EUCAST Clinical breakpoints table v. 10.0, valid from January 2020. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet."	
WS1822 **Relvar Ellipta-EMEA/H/C/002673/ WS1822/0045** **Revinty Ellipta-EMEA/H/C/002745/ WS1822/0043** GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 5.1 of the SmPC to include descriptive data from a study investigating bronchoprotective and HPA-axis effects of fluticasone furoate versus fluticasone propionate or budesonide in an escalating repeat-dose, placebo-controlled, crossover study (study 203162) in 54 adults with a history of asthma, characterised by airway hyperresponsiveness and FEV1 ≥65% predicted. In addition, the MAH has taken the opportunity to add a text related to SUMMIT data to section 5.1 of the high strength label (184/22 mcg) for Relvar/Revinty Ellipta. The text was agreed in procedure EMEA/H/C/2673/WS/0992, however the change was mistakenly not implemented to the SmPC during this procedure. Furthermore, additional minor modifications are introduced in the product information to bring it in line with the QRD template. Consequently, amendments to annex II, IIIA and IIIB are also introduced." Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 15.10.2020, 25.06.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1877 **Invega-EMEA/H/C/000746/WS1877/0068**	

Paliperidone Janssen-Cilag International-EMEA/H/C/005486/WS1877/0001 **Trevicta-EMEA/H/C/004066/WS1877/0026** **Xeplion-EMEA/H/C/002105/WS1877/0051** Janssen-Cilag International NV, Lead Rapporteur: Kristina Dunder, "to add a new post-marketing adverse drug reaction (ADR) " Stevens-Johnson syndrome/toxic epidermal necrolysis" to section 4.8 (Undesirable effects) of the Summary of Product Characteristics (SmPC) for 4 centrally authorised medicinal products (INVEGA/XEPLION/TREVICTA/Paliperidone Janssen-Cilag International) and 2 medicinal products authorised via MRP (Risperdal Oral and Risperdal Consta). Section 4 of the Package Leaflet (PL) for each medicinal product is also amended accordingly."	
WS1917 **Kivexa-EMEA/H/C/000581/WS1917/0087** **Triumeq-EMEA/H/C/002754/WS1917/0085** **Trizivir-EMEA/H/C/000338/WS1917/0119** **Ziagen-EMEA/H/C/000252/WS1917/0114** ViiV Healthcare B.V., Lead Rapporteur: Jean-Michel Race, "Update of sections 4.4 of the SmPC (for Ziagen, Kivexa, Trizivir and Triumeq) and 5.2 (for Triumeq only) to add new information about the drug-drug interactions between abacavir and riociguat. The Package Leaflet is updated accordingly. Furthermore, the MAH took the opportunity to introduce an excipient update for Ziagen, Kivexa and Trizivir in line with the SmPC guideline, a syringe instruction update in the Package Leaflet of Ziagen and a revised statement in section 6.6 of the SmPC for Triumeq in line with the QRD template. Moreover, minor editorial updates have been introduced throughout the Product Information of all four products." Request for Supplementary Information adopted on 19.11.2020.	Request for supplementary information adopted with a specific timetable.
WS1922 **Lixiana-EMEA/H/C/002629/WS1922/0028** **Roteas-EMEA/H/C/004339/WS1922/0016** Daiichi Sankyo Europe GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.2 and 5.2 of the SmPC, based on	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

data from the bioavailability study DU176b-A-U166, in order to add information about the bioavailability of edoxaban crushed tablet administered by nasogastric tube or in apple puree and ingested versus the current tablet formulation in healthy subjects. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to correct typos in Lithuanian, Slovakian and Portuguese versions of the SmPC, Labelling and Package Leaflet."
Opinion adopted on 26.11.2020.

WS1939
Vfend-EMEA/H/C/000387/WS1939/0139
Pfizer Europe MA EEIG, Lead Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.3 and 4.5 of the SmPC in order to add a new contraindication with ivabradine to the contraindications, and add drug-drug interaction information between voriconazole and ivabradine and venetoclax to the Interactions section. The Package Leaflet is updated accordingly.
In addition, the WSA took the opportunity to align with the current Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668), 22 November 2019, EMA/CHMP/302620/2017 Rev. 1*, for lactose, and to update the list of local representatives in the Package Leaflet."

B.5.3. CHMP-PRAC assessed procedures

Imfinzi - durvalumab -
EMEA/H/C/004771/II/0023
AstraZeneca AB, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: David Olsen, "Update of sections 4.2 and 5.1 of the SmPC in order to introduce a new posology regimen of 1500 mg every 4 weeks (Q4W) for the approved indication of the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy. The RMP version 4.1 has also been submitted."
Request for Supplementary Information adopted

on 12.11.2020, 15.10.2020.	
Lynparza - olaparib - EMEA/H/C/003726/II/0042 AstraZeneca AB, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Amelia Cupelli, "Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to add Myelodysplastic syndrome (MDS)/Acute myeloid leukaemia (AML) to the list of adverse drug reactions with the frequency uncommon, modify the existing warning on MDS/AML and update efficacy information based on final results from study SOLO-2 listed as a PAES in the Annex II; this is a phase III randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients who are in complete or partial response following platinum based chemotherapy; the Package Leaflet and Annex II are updated accordingly. The RMP version 21 has also been submitted."	
Lyxumia - lixisenatide - EMEA/H/C/002445/II/0030 sanofi-aventis groupe, Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin, "Submission of the final report from study TDR14311 listed as a category 3 study in the RMP, and submitted in accordance with article 46. This is a Randomized, double-blind, placebo-controlled, dose escalation, study on safety, pharmacokinetics and pharmacodynamics of lixisenatide in paediatric patients with Type 2 diabetes mellitus not adequately controlled with metformin and/or basal insulin. The RMP version 6.0 has also been submitted."	
Natpar - parathyroid hormone - EMEA/H/C/003861/II/0026, Orphan Shire Pharmaceuticals Ireland Limited, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Rhea Fitzgerald, "Submission of the final results of study PAR-C10-008; a long-term open-label study investigating the safety and tolerability of a rhPTH[1-84] for the treatment of adults with hypoparathyroidism – a clinical extension study (RACE). Update of SmPC section 5.1 to reflect 72 month data from the study. Update of the RMP (version 3.0) with the completed study results, to remove this study	Request for supplementary information adopted with a specific timetable.

as an additional pharmacovigilance activity and to align with the GVP module V Rev 2." Request for Supplementary Information adopted on 26.11.2020.	
Ocrevus - ocrelizumab - EMEA/H/C/004043/II/0020 Roche Registration GmbH, Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 5.3 of the SmPC in order to update information on embryo-fetal and pre- and postnatal development in cynomolgus monkeys based on final results from study 17-1133 listed as a Category 3 study in the RMP (MEA 006). The RMP v. 5.0 has also been submitted." Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 01.10.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
OFEV - nintedanib - EMEA/H/C/003821/II/0038 Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.5, 4.6 and 5.2 of the SmPC in order to add drug-drug interaction information with the oral contraceptive Microgynon, a combination of ethynilestradiol and levonorgestrel based on final results from clinical study №1199-0340. This was a phase I, open-label, 2-period cross-over, fixed-sequence design trial, investigated the effect of multiple oral doses of nintedanib on the single dose kinetics of a combination of ethinylestradiol and levonorgestrel (Microgynon). The Package Leaflet is updated accordingly. The RMP is likewise updated to version 10." Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 01.10.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0009/G Portola Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "C.I.4, C.I.3, C.I.6 (non-EoI) Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on results from study CSR 19-514 (PK Comparability) and CSR 16-508 (Japanese Ethnicity Study) listed as a specific obligation in	

the Annex II. Annex II was proposed to be updated accordingly. The RMP version 2.1 has also been submitted." Request for Supplementary Information adopted on 30.04.2020.	
Orbactiv - oritavancin - EMEA/H/C/003785/II/0030 Menarini International Operations Luxembourg S.A., Rapporteur: Janet Koenig, PRAC Rapporteur: Adam Przybylkowski, "Submission of the final report from 14-TMC-01, a Surveillance study investigation, listed as a category 3 study in the RMP, part of the global SENTRY Antimicrobial Surveillance Program platform to monitor the activity of oritavancin against Gram-positive clinical isolates collected from Europe and the US. This application addresses PAM MEA 003.4, presenting the cumulative surveillance data from 2010 to 2019 (including the first 5-year post-approval period). The RMP version 3.1 is approved with this variation." Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 03.09.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Rubraca - rucaparib - EMEA/H/C/004272/II/0023 Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin, "Update of sections 4.5, 4.6 and 5.2 of the SmPC to add drug-drug interaction (DDI) information with rosuvastatin and oral contraceptives based on the results of study CO-338-095 listed as a category 3 study in the RMP; Study CO-338-095 is a phase 1, open-label, DDI study to determine the effect of rucaparib on the pharmacokinetics of oral rosuvastatin (Arm A) and oral contraceptives (ethinylestradiol and levonorgestrel - Arm B) in patients with advanced solid tumours. The RMP version 6.0 has also been submitted." Opinion adopted on 26.11.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Rydapt - midostaurin - EMEA/H/C/004095/II/0014, Orphan Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "C.I.4	

Update of sections 4.2, 4.4, and 5.1 of the SmPC in order to change posology recommendations and add Special warnings and precautions for use in Paediatric population following the occurrence of severe dose limiting toxicities (DLTs) in the paediatric study CPKC412A2218 . The study is part of the agreed PIP (EMEA-000780-PIP01-09-M05) for which a Request for Modification was submitted on 20-Apr-2020 (RSI/Opinion by PDCO expected on 24-Jul-2020). Section 5.1 of the SmPC and the Package Leaflet are updated accordingly. The RMP version 5.0 has also been submitted. In addition, the MAH takes this opportunity to introduce minor editorial changes to align the PI to the updated QRD template version 10.1." Request for Supplementary Information adopted on 17.09.2020.	
Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0037 GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, PRAC Rapporteur: Sonja Hrabcik, "To update sections 4.4 and 5.1 of the SmPC following the final results from study ZOSTER-064, listed as a category 3 study in the RMP; this is an observational study to assess frailty and other prognostic factors for development of herpes zoster in adult subjects who participated in studies ZOSTER-006 and ZOSTER-022 and the HZ efficacy, immunogenicity and safety of Shingrix by frailty status, in order to fulfil the post-authorisation measure MEA/FSR 012. The updated RMP version 4.1 has also been submitted. The MAH takes the opportunity to implement some editorial changes in sections 4.4 and 5.1. and correction of the abbreviation CHO cells from Chinese Hamster Ovarian cells to Chinese Hamster Ovary cells in the Annex A." Request for Supplementary Information adopted on 26.11.2020.	Request for supplementary information adopted with a specific timetable.
Sivextro - tedizolid phosphate - EMEA/H/C/002846/II/0037 Merck Sharp & Dohme B.V., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon, "Update of section 5.1 of the SmPC in order to update the description of the potential risk of emergence of drug resistance with tedizolid phosphate, based on final results from	Request for supplementary information adopted with a specific timetable.

study Surveillance of Tedizolid Activity and Resistance (STAR) listed as a category 3 study in the RMP; this is a surveillance study established in January 2014 to monitor tedizolid susceptibility activity and emergence of resistance across the US, 11 European Union countries, Russia and Turkey. The RMP version 6.2 has also been submitted." Request for Supplementary Information adopted on 26.11.2020, 03.09.2020.	
Vizimpro - dacomitinib - EMEA/H/C/004779/II/0003/G Pfizer Europe MA EEIG, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2 and 5.2 of the SmPC in order to revise the dosing recommendation for patients with hepatic impairment and include relevant pharmacokinetics data based on results of study A7471058, evaluating the effect of severe hepatic impairment on the plasma PK, safety and tolerability after a single dose of dacomitinib. As a consequence, the MAH is proposing to remove the missing information "Safety in Patient with Severe Hepatic Impairment" from the list of safety concerns in the RMP. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1. The MAH has also taken the opportunity to update the EU RMP to include PASS Study A7471064 "Single Arm Study to Evaluate the Safety of Dacomitinib for the First-Line Treatment of Participants in India with Metastatic NSCLC with Epidermal Growth Factor Receptor (EGFR)-Activating Mutations" as a "Category 3 required additional pharmacovigilance activity". A revised RMP v1.1 (clean and tracked) has been submitted." Request for Supplementary Information adopted on 15.10.2020.	
Xeljanz - tofacitinib - EMEA/H/C/004214/II/0027 Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of sections 4.1, 4.2, 4.4 , 4.8, 5.1 and 5.2 of Xeljanz 11 mg prolonged-release tablets SmPC in order to include the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate	See agenda 9.1

response or who have been intolerant to a prior disease modifying antirheumatic drug therapy; as an alternative to the immediate release film-coated tablets; Section 4.2 of Xeljanz film-coated tablets is also updated to include switching with the prolonged-release tablet in the treatment of PsA. The Package Leaflet is updated accordingly. The RMP version 13.1 has also been submitted."	
Xtandi - enzalutamide - EMEA/H/C/002639/II/0049 Astellas Pharma Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, "Update of sections 4.7, 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy and safety information based on final results from study MDV3100-14 (PROSPER) listed as a PAES in the Annex II; this is a phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of enzalutamide in patients with nonmetastatic castration-resistant prostate cancer; the Package Leaflet and Annex II are updated accordingly. The RMP version 14.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, make few editorial updates and bring the PI in line with the latest QRD template version 10.1." Request for Supplementary Information adopted on 26.11.2020, 03.09.2020.	Request for supplementary information adopted with a specific timetable.
Zykadia - ceritinib - EMEA/H/C/003819/II/0034 Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to reflect the results of study CLDK378A2112 as recommended by the CHMP. The study assesses the steady-state PK of 450 mg or 600 mg ceritinib taken daily with a low-fat meal as compared with that of 750 mg ceritinib taken daily in the fasted state in patients with metastatic ALK-positive NSCLC. The Package Leaflet is updated accordingly. The RMP version 16 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1. Other editorial changes include the addition of the sodium content in the SmPCs and PLs and the removal of the black triangle." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 26.11.2020.	
WS1844 **Edistride-EMEA/H/C/004161/WS1844/0039** **Forxiga-EMEA/H/C/002322/WS1844/0057** AstraZeneca AB, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, "Re-categorisation of the Forxiga/Edistride PASS (D169C00011): Retrospective Cohort Study on the Risk of Diabetic Ketoacidosis (DKA) to determine the effectiveness of additional risk minimisation measures in place for DKA by assessing the impact of the risk minimisation measures on the risk of DKA in T1DM patients who are treated with dapagliflozin in Europe, from a category 1 to category 3 PASS in the RMP Version 20 and removal of the following Annex IID of the PI: Obligation to conduct the following Non-interventional PASS: In order to estimate the incidence of DKA in T1DM dapagliflozin users following implementation of RMMs in Europe, the MAH should conduct and submit the results from an observational cohort study using existing data sources in European countries where dapagliflozin will be launched for T1DM, due by 31/12/2026" Request for Supplementary Information adopted on 15.10.2020, 23.07.2020.	See agenda 9.1 and 2.3

B.5.4. PRAC assessed procedures

PRAC Led **Brineura - cerliponase alfa - EMEA/H/C/004065/II/0027, Orphan** BioMarin International Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "An update to the RMP, to change the final date for the completion of the Post-authorisation efficacy study 190-203." Request for Supplementary Information adopted on 26.11.2020.	Request for supplementary information adopted with a specific timetable.
PRAC Led **DaTSCAN - ioflupane (123I) - EMEA/H/C/000266/II/0060** GE Healthcare B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau,	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

"Submission of the first RMP" Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 03.09.2020.	
PRAC Led **EXJADE - deferasirox - EMEA/H/C/000670/II/0068** Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report related to the Physician Survey (NO6987) conducted for Exjade to assess the impact of educational materials on the prescribers' awareness of doses and biological monitoring recommendations and to assess the awareness and appropriate use of both formulations (Dispersible Tablets and Film-Coated tablets). The updated RMP version 17.1 is submitted as well." Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 03.09.2020, 17.04.2020, 16.01.2020, 03.10.2019.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0079** Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report from study ALGMYC07390, Prevalence of immunology testing in patients treated with alglucosidase alfa with significant hypersensitivity/anaphylactic reactions (MEA 053 resulting from variation EMEA/H/C/000636/II/0052) to test the effectiveness of the approved Safety Information Packet (SIP)." Request for Supplementary Information adopted on 26.11.2020, 09.07.2020, 12.03.2020.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Neulasta - pegfilgrastim - EMEA/H/C/000420/II/0113** Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final report from study 20160176 listed as a category 3 study in	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

the RMP. This is a retrospective cohort study with primary outcome the time from index date to diagnosis of MDS or AML (safety). As a result, sections 4.4 and 4.8 of the SmPC is updated to add a new warning on Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), and to add them in the list of adverse drug reactions (ADRs) with frequency uncommon; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1." Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 09.07.2020.	
PRAC Led **Neuraceq - florbetaben (18F) - EMEA/H/C/002553/II/0033** Life Radiopharma Berlin GmbH, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final report from study FBB-01_03_13 (PASS-2) (listed as a category 3 study in the RMP): a non-interventional, cross-sectional, retrospective, multicentre, multi-country registry to observe usage pattern, safety and tolerability of the diagnostic agent NeuraCeq (florbetaben (18F)) in European clinical practice. The RMP (version 5.9) is updated accordingly" Request for Supplementary Information adopted on 26.11.2020.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Ontruzant - trastuzumab - EMEA/H/C/004323/II/0026** Samsung Bioepis NL B.V., Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the RMP version 4.0 in order to propose the early termination of long-term observational follow up study for cardiac safety (SB3-G31-BC-E)." Opinion adopted on 26.11.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Orfadin - nitisinone - EMEA/H/C/000555/II/0074** Swedish Orphan Biovitrum International AB, PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, "Submission of the	Request for supplementary information adopted with a specific timetable.

final report from study Sobi.NTBC-005 listed as a category 3 study in the RMP. This is a non-interventional Post Authorization Safety Study (PASS) to evaluate long-term safety of Orfadin treatment in hypertyrosinemia type 1 (HT-1) patients in standard clinical care. The RMP version 5.3 has also been submitted." Request for Supplementary Information adopted on 26.11.2020, 03.09.2020.	
PRAC Led **Pioglitazone Accord - pioglitazone - EMEA/H/C/002277/II/0020** Accord Healthcare S.L.U., Generic, Generic of Actos, Rapporteur: Peter Kiely, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Peter Kiely, "Update of the Risk Management Plan (RMP) for the removal of safety concerns and additional risk minimisation measures (ARRM) as per summary of RMP of Glidipion (pioglitazone; published on 20-Jul-2020), and content adapted to the new GVP Module V (Rev.2)." Opinion adopted on 26.11.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Piqray - alpelisib - EMEA/H/C/004804/II/0001** Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 2.0 in order to replace the category 3 studies CBYL719C2402 and CBYL719A0IC02 with a new non interventional safety study (CBYL719C2404). Additionally, a separated Health Care Professional Survey (CBYL719A0IC02) is proposed as part of the pharmacovigilance plan." Request for Supplementary Information adopted on 26.11.2020.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Replagal - agalsidase alfa - EMEA/H/C/000369/II/0106** Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Update of sections 4.8 and 4.4 of the Summary of Product Characteristics (SmPC) in order to update the list of adverse drug reactions (ADRs)	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

information based on the final results from study HGT-REP-081 " a Multicenter Open-label Treatment Protocol to Observe the Safety of Replagal (agalsidase alfa) Enzyme Replacement Therapy in Canadian Patients with Fabry Disease" and the safety information reported in clinical trials. In addition, the MAH took the opportunity to introduce editorial and QRD changes in sections throughout the Product Information according to the QRD templates and current guidelines, including new warnings related to sodium excipient and traceability of biological medicinal products. The Package Leaflet is updated accordingly." Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 14.05.2020.	
PRAC Led **Stelara - ustekinumab - EMEA/H/C/000958/II/0082** Janssen-Cilag International NV, Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "To submit the final safety registry report of CNTO1275PSO4005 "Nordic Database Initiative for Exposure to Ustekinumab: a Review and Analysis of Adverse Events from the Swedish and Danish National Registry Systems" listed as a category 3 in the RMP. An updated RMP version (18.2) has also been submitted." Request for Supplementary Information adopted on 26.11.2020.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Trulicity - dulaglutide - EMEA/H/C/002825/II/0051** Eli Lilly Nederland B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Ilaria Baldelli, PRAC-CHMP liaison: Armando Genazzani, "Submission of the final study report for the PASS category 3 dulaglutide drug utilisation study B009: a multi-database collaborative research program of observational studies to monitor the utilisation and safety of dulaglutide in the EU (ref. PAM MEA 002-002.5). An updated RMP version 6.1 was provided as part of the application." Request for Supplementary Information adopted on 26.11.2020, 09.07.2020.	Request for supplementary information adopted with a specific timetable.
PRAC Led **VPRIV - velaglucerase alfa -**	Request for supplementary information adopted with a specific timetable.

EMEA/H/C/001249/II/0049, Orphan Shire Pharmaceuticals Ireland Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of final physician data study results for PASS study "Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey among Health Care Professionals and Patient/Caregivers to Assess their Knowledge and Attitudes on Prescribing and Home Administration Conditions of Velaglucerase Alpha (VPRIV) in 6 European Countries" (EUPASS 14255)" Request for Supplementary Information adopted on 26.11.2020.	
PRAC Led **Zinforo - ceftaroline fosamil - EMEA/H/C/002252/II/0055** Pfizer Ireland Pharmaceuticals, Rapporteur: Alar Irs, PRAC Rapporteur: Maia Uusküla, PRAC-CHMP liaison: Alar Irs, "Update of sections 4.4 and 5.2 of the SmPC in order to include information on the use of ceftaroline in patients with cystic fibrosis, based on a pooled population pharmacokinetic (Pop PK) analysis that included data from cystic fibrosis patients treated with ceftaroline fosamil. This submission fulfils the post-authorisation measure LEG 016.1. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial changes." Request for Supplementary Information adopted on 26.11.2020.	Request for supplementary information adopted with a specific timetable.
PRAC Led **WS1653 Enbrel-EMEA/H/C/000262/WS1653/0230 LIFMIOR (EXP)-EMEA/H/C/004167/ WS1653/0024** Pfizer Europe MA EEIG, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Submission of the second 5-year report from the British Society for Rheumatology Biologics Register (BSRBR, also referred as study B1801309) listed as a category 3 study in the RMP. This is a prospective observational cohort study which investigates the long-term outcomes of patients with rheumatoid arthritis treated with etanercept with particular reference to safety."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 26.11.2020, 17.04.2020, 16.01.2020.	
PRAC Led **WS1760** **Lixiana-EMEA/H/C/002629/WS1760/0024** **Roteas-EMEA/H/C/004339/WS1760/0011** Daiichi Sankyo Europe GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final study report from study ETNA-DUS: a retrospective drug utilisation chart review study listed as a category 3 study in the RMP. The Edoxaban Treatment in Routine Clinical Practice Drug Utilisation Study (ETNA-DUS) was designed to gain insight on how edoxaban is used in real practice. The ETNA-DUS intends to help identify prescription patterns and the effectiveness of the educational programs" Opinion adopted on 26.11.2020. Request for Supplementary Information adopted on 14.05.2020, 16.01.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **WS1861/G** **Kisplyx-EMEA/H/C/004224/WS1861/0037/G** **Lenvima-EMEA/H/C/003727/WS1861/0037/G** Eisai GmbH, Lead Rapporteur: Karin Janssen van Doorn, Lead PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final clinical study report (CSR) for Study E7080-G000-201 (Study 201) - To evaluate the long-term safety of lenvatinib in Medullary and Iodine-131 Refractory, Unresectable differentiated thyroid carcinoma (DTC), Stratified by Histology (MEA 001 for Lenvima; from initial MAA for Kisplyx). Submission of the final CSR for Study E7080-G000-303 (Study 303) - To evaluate long-term safety of lenvatinib in patients with RR-DTC (radioiodine refractory differentiated thyroid cancer) in a randomized, double-blind, placebo-controlled Phase 3 study (MEA 004 for Lenvima; MEA 002 for Kisplyx). Submission of an updated integrated summary of safety (ISS) including data from DTC subjects in Studies 201, 303 and E7080-J081-208 (Study 208) - the latter study was to determine the long-term safety profile of lenvatinib in	

Japanese patients with advanced thyroid cancer (Kisplyx REC from Study 208 variation (procedure EMEA/H/C/003727/II/0008) for Lenvima). The RMP version 12 has also been submitted." Request for Supplementary Information adopted on 03.09.2020.	
PRAC Led **WS1944** **Izba-EMEA/H/C/002738/WS1944/0014** **Travatan-EMEA/H/C/000390/WS1944/0064** Novartis Europharm Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Eva A. Segovia, "To submit and updated RMP for Travatan and Izba with the following proposed changes: The following risks are proposed for removal in this RMP update: important identified risks - Macular oedema - Hyperpigmentation - Hypertrichoses - Iris and uveal inflammations - Cardiac and vascular disorders - Respiratory disorders - Hypersensitivity reactions important potential risks: - Melanoma - Corneal damage due to use of preserved eye drops - Use during pregnancy and lactation removal of the following missing information topics: - Long-term safety in the paediatric population - Potential interactions In addition, the format of the Risk management plan has been aligned with GVP Module V Revision 2 requirements (EMA 2017). The changes made to the RMP were performed following the PRAC recommendation dated 31-Oct-2019 for the recent PSUR with PSUR number PSUSA/003011/201902." Opinion adopted on 26.11.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **WS1972** **Exviera-EMEA/H/C/003837/WS1972/0049** **Viekirax-EMEA/H/C/003839/WS1972/0060**	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Maria del Pilar Rayon, "To provide an updated Risk Management Plans (RMP) for Viekirax and Exviera following the outcome of procedure EMEA/H/C/PSA/J/0055 to change the due date for submission of the final study report for the HCC recurrence PASS study ."
Opinion adopted on 26.11.2020.

B.5.5. CHMP-CAT assessed procedures

Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0027, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, Co-Rapporteur: Dariusz Sladowski, CHMP Coordinators: Ingrid Wang and Ewa Balkowiec Iskra
Request for Supplementary Information adopted on 06.11.2020, 09.10.2020.

Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0008, Orphan, ATMP
Novartis Gene Therapies EU Limited, Rapporteur: Johannes Hendrikus Ovelgonne, Co-Rapporteur: Egbert Flory, CHMP Coordinators: Johann Lodewijk Hillege and Jan Mueller-Berghaus, , "Update to SmPC for sections 4.4 (Special warnings and precautions for use), 4.8 (Undesirable Effects) and corresponding sections in the Package Leaflet to add a new safety signal of 'Thrombotic microangiopathy'."

Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0009/G, Orphan, ATMP
Novartis Gene Therapies EU Limited, Rapporteur: Johannes Hendrikus Ovelgonne, Co-Rapporteur: Egbert Flory, CHMP Coordinators: Johann Lodewijk Hillege and Jan Mueller-Berghaus

Zynteglo - betibeglogene autotemcel - EMEA/H/C/003691/II/0017, Orphan, ATMP
bluebird bio (Netherlands) B.V, Rapporteur: Carla Herberts, Co-Rapporteur: Violaine Closson Carella, CHMP Coordinators Paula Boudewina

van Hennik and Alexandre Moreau

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS1834 **Aerius-EMEA/H/C/000313/WS1834/0094** **Azomyr-EMEA/H/C/000310/WS1834/0098** **Neoclarityn-EMEA/H/C/000314/WS1834/0092** Merck Sharp & Dohme B.V., Duplicate, Duplicate of Allex (SRD), Azomyr, Opulis (SRD), Lead Rapporteur: Christophe Focke, "The scope of this variation is to update the Product information to comply with the revised Annex to the European Commission guideline on "Excipients in the labelling and package leaflet of medicinal products for human use". To update sections 2., 4.4 and 6.1 (6.1 only for oral solution) of the SmPC to reflect that the guidance on excipients has been changed. Section 2 of the Package Leaflet is updated accordingly. Additionally SmPC, PIL and Labelling were updated to the latest QRD version and some minor corrections of the text introduced also affecting other sections, which do not have impact on the content."	
WS1878 **Ambirix-EMEA/H/C/000426/WS1878/0110** **Fendrix-EMEA/H/C/000550/WS1878/0073** **Infanrix hexa-EMEA/H/C/000296/WS1878/0284** **Twinrix Adult-EMEA/H/C/000112/WS1878/0145** **Twinrix Paediatric-EMEA/H/C/000129/WS1878/0146** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 26.11.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1890 **Infanrix hexa-**	

EMEA/H/C/000296/WS1890/0286 GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke	
WS1895/G **Lixiana-EMEA/H/C/002629/WS1895/0029/G** **Roteas-EMEA/H/C/004339/WS1895/0017/G** Daiichi Sankyo Europe GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro Opinion adopted on 26.11.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1905 **Infanrix hexa-EMEA/H/C/000296/WS1905/0283** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 26.11.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1912 **Ambirix-EMEA/H/C/000426/WS1912/0111** **Infanrix hexa-EMEA/H/C/000296/WS1912/0285** **Rotarix-EMEA/H/C/000639/WS1912/0117** **Twinrix Adult-EMEA/H/C/000112/WS1912/0146** **Twinrix Paediatric-EMEA/H/C/000129/WS1912/0147** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 26.11.2020.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1930 **Hexacima-EMEA/H/C/002702/WS1930/0107** **Hexaxim-EMEA/H/W/002495/WS1930/0112** **Hexyon-EMEA/H/C/002796/WS1930/0111** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus	
WS1931 **Hirobriz Breezhaler-EMEA/H/C/001211/WS1931/0060** **Onbrez Breezhaler-EMEA/H/C/001114/WS1931/0058** **Oslif Breezhaler-EMEA/H/C/001210/WS1931/0058** Novartis Europharm Limited, Lead Rapporteur: Kirstine Moll Harboe, "To update SmPC sections	

4.4 and 5.1 (indacaterol maleate) on LABA components and to make changes related to QT interval prolongation. In addition the MAH has taken this opportunity to bring the annexes in line with QRD version 10.1 and to update the instruction for use in SmPC section 6.6 and package leaflet.”	
WS1940 **Adcirca-EMEA/H/C/001021/WS1940/0033** **Cialis-EMEA/H/C/000436/WS1940/0093** **Tadalafil Lilly-EMEA/H/C/004666/ WS1940/0006** Eli Lilly Nederland B.V., Lead Rapporteur: Maria Concepcion Prieto Yerro, “To include the excipient guidance in the labelling and package leaflet annex. In addition the QRD template has also been implemented. i.e. the MAH has updated the order of presentation in line with QRD for Cialis and Tadalafil Lilly. The details of the local representatives in Lithuania, Latvia, Estonia, France and Slovakia have been updated.” Request for Supplementary Information adopted on 26.11.2020.	Request for supplementary information adopted with a specific timetable.
WS1950 **Kinzalmono-EMEA/H/C/000211/ WS1950/0116** **Micardis-EMEA/H/C/000209/WS1950/ 0119** **Pritor-EMEA/H/C/000210/WS1950/0129** Boehringer Ingelheim International GmbH, Lead Rapporteur: Armando Genazzani, “To update section 4.4 of the SmPC and section 2 of the PL in order to implement the wording in compliance with the revised “Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668), Revision 1 related to sorbitol and sodium content. Furthermore, MAH took this opportunity to implement QRD template version 10.1. Section 6 of the PL was updated to add 'K25' to povidone. Finally, some editorial changes to correct the provided administrative information of the PI are included in the submission: - For Kinzalmono/Pritor: § Correction of the date of latest renewal in section 9 of the SmPC.	Positive Opinion adopted by consensus on 26.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

§ Change of the phone number of local representative of MAH in Bulgaria in in section 6 of PL. - For Micardis: § Change of the phone number of local representative of MAH in Austria and Lithuania in section 6 of PL. § Removal of "D-" from the zip code of address of MAH and manufacturer in section 7 of the SmPC, section A of the Annex II, section 6 of the PL and section 11 of the Labelling. - Addition of minor linguistic corrections to the PI of the following languages: LT, FI, SV and EL. Further the MAH took the opportunity and include an editorial change ." Opinion adopted on 26.11.2020.	
WS1951 **Combivir-EMEA/H/C/000190/WS1951/0098** **Telzir-EMEA/H/C/000534/WS1951/0102** ViiV Healthcare B.V., Lead Rapporteur: Jean-Michel Race, "To update section 4.4 of the SmPC and section 2 of the PL to update excipients labelling in alignment with excipients guideline (Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668) related to sodium content for: - Telzir (fosamprenavir) 700 mg Film-coated tablets; - Combivir (lamivudine/zidovudine) 150/300 mg Film-coated tablets. In addition, the MAH took the opportunity to apply minor administrative changes in the following languages: LT, SL and FR."	
WS1955 **Exelon-EMEA/H/C/000169/WS1955/0130** **Prometax-EMEA/H/C/000255/WS1955/0130** Novartis Europharm Limited, Lead Rapporteur: Alexandre Moreau, "To update sections 2 and 4.4 of the SmPC for Exelon 2mg/mL Oral Solution and Prometax 2mg/mL Oral Solution in line with the current excipients guideline (Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668)) with regards to sodium (from sodium benzoate and sodium citrate dihydrate)	Positive Opinion adopted by consensus on 19.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

and sodium benzoate that are listed under the annex to the excipient guideline. Section 2 of package leaflet (PL) was updated accordingly. In addition, the MAH took this opportunity to bring the product information annexes for all presentations in line with the current QRD template." Opinion adopted on 19.11.2020.	
WS1956 **Zypadhera-EMEA/H/C/000890/WS1956/0043** **Zyprexa-EMEA/H/C/000115/WS1956/0130** **Zyprexa Velotab-EMEA/H/C/000287/WS1956/0098** Eli Lilly Nederland B.V., Duplicate, Duplicate of Zyprexa, Lead Rapporteur: Outi Mäki-Ikola, "To include new wording on excipients in SmPC section 4.4 and in the package leaflet. The wording takes the new excipient guidance into account. In addition the MAH has also taken this opportunity to make minor changes in accordance with the QRD template." Opinion adopted on 19.11.2020.	Positive Opinion adopted by consensus on 19.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1958/G **Aflunov-EMEA/H/C/002094/WS1958/0063/G** **Foclivia-EMEA/H/C/001208/WS1958/0059/G** Seqirus S.r.l, Lead Rapporteur: Armando Genazzani	

B.5.9. Information on withdrawn type II variation / WS procedure

WS1884 **Nuwiq-EMEA/H/C/002813/WS1884/0037** **Vihuma-EMEA/H/C/004459/WS1884/0019** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 03.09.2020. Withdrawal request submitted on 19.11.2020.	The MAH withdrew the procedure on 19.11.2020.

Zinforo - ceftaroline fosamil - EMEA/H/C/002252/II/0048 Pfizer Ireland Pharmaceuticals, Rapporteur: Alar Irs, "Extension of the indication for the treatment of community acquired pneumonia (CAP) to include concurrent bacteraemia due to Streptococcus pneumoniae (SP) for all age groups, based on the results of previously submitted studies: FOCUS 1 (study P903-08) and FOCUS 2 (study P903-09), paediatric CAP study (study P903-31) and relevant post-marketing safety experience with ceftaroline for bacteraemic Streptococcus pneumoniae CAP. As a consequence, sections 4.1 and 5.1 of the SmPC are updated accordingly. No RMP has been provided within this application." Request for Supplementary Information adopted on 12.11.2020, 23.07.2020, 12.12.2019.	The MAH withdrew the procedure on 30.11.2020.

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

odevixibat - EMEA/H/C/004691, Orphan Albireo, treatment of progressive familial intrahepatic cholestasis (PFIC)	**Accelerated review**
COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735 Active immunization against COVID-19 disease	
fingolimod - EMEA/H/C/005661 treatment of multiple sclerosis	
finerenone - EMEA/H/C/005200 delay progression of kidney disease, reduce the risk of cardiovascular mortality and morbidity	
maralixibat - EMEA/H/C/005551, Orphan FGK Representative Service GmbH, Treatment of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment of Progressive Familial Intrahepatic Cholestasis Type 2	
metformin hydrochloride / sitagliptin hydrochloride monohydrate - EMEA/H/C/005678 treatment of type 2 diabetes mellitus	

arimoclomol - EMEA/H/C/005203, Orphan
Orphazyme A/S, treatment of Niemann-Pick disease type C (NPC)

COVID-19 mRNA vaccine - EMEA/H/C/005791
indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus in adults aged 18 years and older.

adrenalin - EMEA/H/C/005584
For the emergency treatment of allergic reactions, including anaphylaxis.

lasmiditan - EMEA/H/C/005332
acute treatment of migraine with or without aura in adults

sitagliptin fumarate - EMEA/H/C/005741
treatment of type 2 diabetes mellitus

tepotinib - EMEA/H/C/005524
indicated for the treatment of adult patients with advanced non-small cell lung cancer.

teriparatide - EMEA/H/C/005543
treatment of osteoporosis

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

Noxafil - posaconazole - EMEA/H/C/000610/X/0063/G
Merck Sharp & Dohme B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, "Extension application to introduce a new pharmaceutical form (gastro-resistant powder and solvent for oral suspension), grouped with a type II variation (C.I.6.a) to extend the approved indications for Noxafil to the paediatric population. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC, as well as the package leaflet, are updated. The RMP (version 17.1) is updated in accordance."

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

idecabtagene vicleucel - EMEA/H/C/004662, Orphan, ATMP
Celgene Europe BV, treatment of multiple myeloma

List of Questions adopted on 11.09.2020.

dexamethasone phosphate - EMEA/H/C/005740
indicated for cerebral oedema, post-traumatic shock-lung syndrome, asthma, skin diseases, autoimmune diseases, rheumatoid arthritis, prophylaxis and treatment of post-operative or cytostatic-induced vomiting, treatment of COVID-19, eye inflammation and infection
List of Questions adopted on 15.10.2020.

tanezumab - EMEA/H/C/005189
treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or an opioid is ineffective, not tolerated or inappropriate
List of Questions adopted on 23.07.2020.

relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267
treatment of uterine fibroids
List of Questions adopted on 23.07.2020.

ponesimod - EMEA/H/C/005163
treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features
List of Questions adopted on 23.07.2020.

B.6.4. Annual Re-assessments: timetables for adoption

Defitelio - defibrotide - EMEA/H/C/002393/S/0051, Orphan
Gentium S.r.l., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Orphacol - cholic acid - EMEA/H/C/001250/S/0038, Orphan
Laboratoires CTRS, Rapporteur: Konstantinos Markopoulos, PRAC Rapporteur: Sofia Trantza

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Atazanavir Mylan - atazanavir - EMEA/H/C/004048/R/0016
Mylan S.A.S, Generic, Generic of Reyataz, Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Adrien Inoubli

Bortezomib Hospira - bortezomib - EMEA/H/C/004207/R/0020
Pfizer Europe MA EEIG, Generic, Generic of VELCADE, Rapporteur: Milena Stain, PRAC Rapporteur: Amelia Cupelli

Bortezomib SUN - bortezomib - EMEA/H/C/004076/R/0015
Sun Pharmaceutical Industries Europe B.V., Generic, Generic of VELCADE, Rapporteur: Margareta Bego, PRAC Rapporteur: Amelia Cupelli

Cinqaero - reslizumab - EMEA/H/C/003912/R/0038
Teva B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Brigitte Keller-Stanislawski

Lorviqua - lorlatinib - EMEA/H/C/004646/R/0011
Pfizer Europe MA EEIG, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Nikica Mirošević Skvrce

Nordimet - methotrexate - EMEA/H/C/003983/R/0018
Nordic Group B.V., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Martin Huber

Pandemic influenza vaccine H5N1 AstraZeneca - pandemic influenza vaccine (H5N1) (live attenuated, nasal) - EMEA/H/C/003963/R/0040
AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sonja Hrabcik

Pemetrexed Fresenius Kabi - pemetrexed - EMEA/H/C/003895/R/0023
Fresenius Kabi Deutschland GmbH, Generic, Generic of Alimta, Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Tiphaine Vaillant

Rubraca - rucaparib - EMEA/H/C/004272/R/0025
Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin

Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/R/0012, Orphan, ATMP
Novartis Gene Therapies EU Limited, Rapporteur: Johannes Hendrikus Ovelgonne,

Co-Rapporteur: Egbert Flory, PRAC Rapporteur: Ulla Wändel Liminga

Zynteglo - betibeglogene autotemcel - EMEA/H/C/003691/R/0018, Orphan, ATMP
bluebird bio (Netherlands) B.V, Rapporteur: Carla Herberts, PRAC Rapporteur: Brigitte Keller-Stanislawski

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Darzalex - daratumumab - EMEA/H/C/004077/II/0043, Orphan
Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Extension of indication to include treatment of adult patients with systemic light chain (AL) amyloidosis for Darzalex; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.2 of the RMP has also been submitted."

Darzalex - daratumumab - EMEA/H/C/004077/II/0044, Orphan
Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Extension of indication for Darzalex subcutaneous formulation to include combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. In addition, section 4.8 of the SmPC for the intravenous formulation is also updated based on the pooled safety analysis. The Package Leaflet is updated in accordance. Version 8.2 of the RMP has also been submitted."

Keytruda - pembrolizumab -

EMEA/H/C/003820/II/0097

Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Extension of indication to include in combination with chemotherapy, first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults for Keytruda, based on the results from the pivotal KEYNOTE-590 (KN590) trial. Phase 3, randomized, double-blind, placebo-controlled, multisite study to evaluate the efficacy and safety of pembrolizumab in combination with chemotherapy (cisplatin and 5-FU) versus chemotherapy (cisplatin with 5-FU) as first line treatment in participants with locally advanced unresectable metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction; as a consequence sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version of the RMP (Version 30.1) has also been submitted."

Tecentriq - atezolizumab - EMEA/H/C/004143/II/0052

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Extension of indication to include Tecentriq in combination with nab-paclitaxel and anthracycline-based chemotherapy for the neoadjuvant treatment of adult patients with locally advanced or early Triple Negative Breast Cancer (TNBC) based on the results of the pivotal study WO39392 (IMpassion031); as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the Tecentriq 840 mg concentrate for solution for infusion SmPC and section 4.8 of the Tecentriq 1,200 mg concentrate for solution for infusion SmPC are updated. The Package Leaflet is updated in accordance. Version 18 of the RMP has also been submitted."

Verzenios - abemaciclib - EMEA/H/C/004302/II/0013

Eli Lilly Nederland B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Marcia Sofia

Sanches de Castro Lopes Silva, "Extension of indication to include Verzenios in combination with endocrine therapy for adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence; as a consequence, section 4.1, 4.2, 4.4, 4.6, 4.8, 5.1 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
WS1941 **Edistride-EMEA/H/C/004161/WS1941/0043** **Forxiga-EMEA/H/C/002322/WS1941/0062** AstraZeneca AB, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, "Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC for Forxiga and Edistride based on the results from the renal outcomes study D169AC00001 (DAPA-CKD). The Annex II.B and Package Leaflet of these products are updated accordingly. The DAPA-CKD study is a category 3, Post-Authorisation Safety Study (PASS) listed in the dapagliflozin RMP to evaluate the potential risk of lower limb amputation; it is a multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death. In addition, the Risk Management Plan for dapagliflozin (version 22) has been updated."	
WS1953 **Segluromet-EMEA/H/C/004314/WS1953/0012** **Steglatro-EMEA/H/C/004315/WS1953/0013** Merck Sharp & Dohme B.V., Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Menno van der Elst, "Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC of Steglatro and Segluromet in order to modify the indication, update posology recommendations and include	

efficacy and safety information based on final results from the VERTIS CV study (protocol 8835-004/B1521021) listed as a category 3 study in the RMP. This is a multi-centre, multi-national, randomised, double-blind, placebo-controlled study to evaluate the effect of ertugliflozin on cardiovascular risk in adult patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Abasaglar - insulin glargine - EMEA/H/C/002835/II/0035/G
Eli Lilly Nederland B.V., Rapporteur: Kristina Dunder

AYVAKYT - avapritinib - EMEA/H/C/005208/II/0002, Orphan
Blueprint Medicines (Netherlands) B.V., Rapporteur: Blanca Garcia-Ochoa

AYVAKYT - avapritinib - EMEA/H/C/005208/II/0003/G, Orphan
Blueprint Medicines (Netherlands) B.V., Rapporteur: Blanca Garcia-Ochoa

Benlysta - belimumab - EMEA/H/C/002015/II/0090
GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder

Darunavir Mylan - darunavir - EMEA/H/C/004068/II/0012
Mylan S.A.S, Generic, Generic of Prezista, Rapporteur: John Joseph Borg

Dupixent - dupilumab - EMEA/H/C/004390/II/0038/G
sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus

EVRA - ethinylestradiol / norelgestromin - EMEA/H/C/000410/II/0048/G
Janssen-Cilag International NV, Rapporteur: Paula Boudewina van Hennik

Firmagon - degarelix - EMEA/H/C/000986/II/0038
Ferring Pharmaceuticals A/S, Rapporteur: Alexandre Moreau

Gardasil 9 - human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMEA/H/C/003852/II/0044
MSD Vaccins, Rapporteur: Kristina Dunder

Herceptin - trastuzumab - EMEA/H/C/000278/II/0166
Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus

Herzuma - trastuzumab - EMEA/H/C/002575/II/0035/G
Celltrion Healthcare Hungary Kft., Rapporteur: Jan Mueller-Berghaus

Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0122
CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

ILARIS - canakinumab - EMEA/H/C/001109/II/0072/G
Novartis Europharm Limited, Rapporteur: Jan Mueller-Berghaus

Inflectra - infliximab - EMEA/H/C/002778/II/0094/G
Pfizer Europe MA EEIG, Duplicate, Duplicate of Remsima, Rapporteur: Outi Mäki-Ikola

Inhixa - enoxaparin sodium - EMEA/H/C/004264/II/0073/G
Techdow Pharma Netherlands B.V., Duplicate, Duplicate of Thorinane (EXP), Rapporteur: Andrea Laslop

Kadcyla - trastuzumab emtansine - EMEA/H/C/002389/II/0053
Roche Registration GmbH, Rapporteur: Sinan B. Sarac

Kovaltry - octocog alfa - EMEA/H/C/003825/II/0033
Bayer AG, Rapporteur: Kristina Dunder

Lucentis - ranibizumab - EMEA/H/C/000715/II/0090/G
Novartis Europharm Limited, Rapporteur: Kristina Dunder

M-M-RVAXPRO - measles, mumps and rubella vaccine (live) - EMEA/H/C/000604/II/0105
MSD Vaccins, Rapporteur: Jan Mueller-Berghaus

MabThera - rituximab -
EMEA/H/C/000165/II/0179
Roche Registration GmbH, Rapporteur: Sinan B. Sarac

Mepsevii - vestronidase alfa -
EMEA/H/C/004438/II/0019, Orphan
Ultragenyx Germany GmbH, Rapporteur: Johann Lodewijk Hillege

MVASI - bevacizumab -
EMEA/H/C/004728/II/0017
Amgen Technology (Ireland) Unlimited Company, Duplicate, Duplicate of KYOMARC, Rapporteur: Bjorg Bolstad

Myalepta - metreleptin -
EMEA/H/C/004218/II/0017/G, Orphan
Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn

Nucala - mepolizumab -
EMEA/H/C/003860/II/0038
GlaxoSmithKline Trading Services Limited, Rapporteur: Peter Kiely

Orfadin - nitisinone -
EMEA/H/C/000555/II/0075
Swedish Orphan Biovitrum International AB, Rapporteur: Armando Genazzani

Ozempic - semaglutide -
EMEA/H/C/004174/II/0019
Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege

POTELIGEO - mogamulizumab -
EMEA/H/C/004232/II/0008, Orphan
Kyowa Kirin Holdings B.V., Rapporteur: Paula Boudewina van Hennik

ProQuad - measles, mumps, rubella and varicella vaccine (live) -
EMEA/H/C/000622/II/0144
MSD Vaccins, Rapporteur: Jan Mueller-Berghaus

Puregon - follitropin beta -
EMEA/H/C/000086/II/0113
Merck Sharp & Dohme B.V., Rapporteur: Peter Kiely

Quofenix - delafloxacin -
EMEA/H/C/004860/II/0007/G
A. Menarini Industrie Farmaceutiche Riunite s.r.l., Rapporteur: Janet Koenig

Remsima - infliximab - EMEA/H/C/002576/II/0096/G
Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola

RoActemra - tocilizumab - EMEA/H/C/000955/II/0098/G
Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus

Soliris - eculizumab - EMEA/H/C/000791/II/0115/G, Orphan
Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa

Surgiflo Haemostatic Matrix Kit - human thrombin - EMEA/H/D/002301/II/0021
Presafe Denmark A/S, Rapporteur: Jan Mueller-Berghaus

Surgiflo Haemostatic Matrix Kit - human thrombin - EMEA/H/D/002301/II/0022
Presafe Denmark A/S, Rapporteur: Jan Mueller-Berghaus

Tecentriq - atezolizumab - EMEA/H/C/004143/II/0051
Roche Registration GmbH, Rapporteur: Sinan B. Sarac

Toujeo - insulin glargine - EMEA/H/C/000309/II/0117/G
Sanofi-Aventis Deutschland GmbH, Duplicate, Duplicate of Lantus, Rapporteur: Johann Lodewijk Hillege

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0070
MCM Vaccine B.V., Rapporteur: Christophe Focke

Votrient - pazopanib - EMEA/H/C/001141/II/0063/G
Novartis Europharm Limited, Rapporteur: Sinan B. Sarac

VPRIV - velaglucerase alfa - EMEA/H/C/001249/II/0051, Orphan
Shire Pharmaceuticals Ireland Limited, Rapporteur: Martina Weise

Zaltrap - aflibercept -

EMEA/H/C/002532/II/0058/G
sanofi-aventis groupe, Rapporteur: Filip Josephson

WS1935
Mircera-EMEA/H/C/000739/WS1935/0083
NeoRecormon-EMEA/H/C/000116/ WS1935/0110
Roche Registration GmbH, Lead Rapporteur: Martina Weise

WS1942/G
Fluenz Tetra-EMEA/H/C/002617/ WS1942/0103/G
Pandemic influenza vaccine H5N1 AstraZeneca-EMEA/H/C/003963/ WS1942/0038/G
AstraZeneca AB, Lead Rapporteur: Christophe Focke

WS1943/G
Fluenz Tetra-EMEA/H/C/002617/ WS1943/0104/G
Pandemic influenza vaccine H5N1 AstraZeneca-EMEA/H/C/003963/ WS1943/0039/G
AstraZeneca AB, Lead Rapporteur: Christophe Focke

WS1954
Infanrix hexa-EMEA/H/C/000296/ WS1954/0289
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS1959
Hexacima-EMEA/H/C/002702/ WS1959/0109
Hexaxim-EMEA/H/W/002495/ WS1959/0114
Hexyon-EMEA/H/C/002796/ WS1959/0113
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

WS1960
Infanrix hexa-EMEA/H/C/000296/ WS1960/0290
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS1974
Ratiograstim-EMEA/H/C/000825/ WS1974/0070

Tevagrastim-EMEA/H/C/000827/ WS1974/0078
TEVA GmbH, Duplicate, Duplicate of Biograstim (SRD), Lead Rapporteur: Outi Mäki-Ikola

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0085, Orphan
Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, "Update of the SmPC section 5.1 with the 5 year long-term follow up and final OS results for the C25007 study in HL. Editorial updates have been also implemented in the PI."

Adjupanrix - pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - EMEA/H/C/001206/II/0072/G
GlaxoSmithkline Biologicals SA, Informed Consent of Pandemrix (EXP), Rapporteur: Johann Lodewijk Hillege, "A grouped application of 3 type II variations under category C.I.13: - Submission of a safety pharmacology study performed to assess the effect of AS03 alone and the adjuvanted influenza antigen on cardiovascular and respiratory of telemetered dogs (study MDS AA80120). - Submission of a biodistribution study (study GSK-CH-02-11) conducted in mice with the 3 components of the AS03 Adjuvant System radio-labelled ([14C]-α-tocopherol, [14C]-squalene, and [3H]-polysorbate) to support the understanding of mode of action of AS03. - Submission of a GLP reproductive and developmental toxicity study (study HLS GVB/007/063710) conducted to evaluate the effect of AS03 on embryo-fetal and peri- and post-natal development in Crl:CD (SD) IGS BR rats following intramuscular administration."

Cosentyx - secukinumab - EMEA/H/C/003729/II/0069
Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola, "Update of section 5.1 of the SmPC based on final results from study CAIN457F3302; this is a randomised, double-blind, placebo-controlled study (MAXIMISE) which assessed the efficacy of secukinumab in PsA patients with axial manifestations who were

naive to biologic treatment and responded inadequately to NSAIDs; the MAH took this opportunity to introduce minor editorial changes in Section 5.1 of the SmPC."

Cyramza - ramucirumab - EMEA/H/C/002829/II/0039

Eli Lilly Nederland B.V., Rapporteur: Paula Boudewina van Hennik, "Update of section 4.8 of the SmPC in order to add hypothyroidism to the list of adverse reactions with a frequency of common based on the updated reference safety information for ramucirumab. The Package Leaflet is also updated. In addition, minor updates are included to the list of local representatives in the product information."

Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0003

International Partnership for Microbicides Belgium AISBL, Rapporteur: Paula Boudewina van Hennik, "Submission of the final bioanalytical (sub)reports or annexes for the long-term stability experiments for the plasma and vaginal fluid samples of studies IPM 027 and IPM 035."

Dupixent - dupilumab - EMEA/H/C/004390/II/0039

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, "To update section 4.8 of the SmPC to replace tables of adverse drug reactions per indication with a consolidated table of adverse drug reactions across all approved indications as agreed in the latest PSUR (EMEA/H/C/PSUSA/00010645/ 202003). The Package Leaflets are updated accordingly."

Enbrel - etanercept - EMEA/H/C/000262/II/0238

Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 4.8 of the SmPC to add headache to the list of adverse drug reactions with a frequency very common; the package leaflet is updated accordingly. In addition, the MAH took the opportunity to remove text for inflammatory bowel disease and uveitis specific to the paediatric population from section 4.4 and 4.8 of the SmPC and the package leaflet for consistency as requested by PRAC in the latest PSUSA (PSUSA/00010795/202002)."

Epivir - lamivudine - EMEA/H/C/000107/II/0114

ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, "Update of sections 5.2 of the SmPC to add new information about the biotransformation of lamivudine. Furthermore, the MAH took the opportunity to introduce an excipient update in line with the SmPC guideline, a syringe and adapter instruction update in the Package Leaflet and a revision of Annex II in line with the QRD template. Moreover, minor editorial updates have been introduced throughout the Product Information."

Eylea - aflibercept - EMEA/H/C/002392/II/0067

Bayer AG, Rapporteur: Alexandre Moreau

Fabrazyme - agalsidase beta - EMEA/H/C/000370/II/0119

Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege, "Submission of the final report following CHMP conclusions on the related post-authorisation measure (MEA 57.12) from the Fabry registry, a global, observational and voluntary program designed to collect uniform and meaningful clinical data related to the onset, progression, and treated course of patients with Fabry disease. This is a long term effectiveness study to enhance the understanding of long-term severe events and clinical continuous outcomes of Fabrazyme among 5 subgroups identified by modified Arends criteria, estimate the disease progression after Fabrazyme treatment among Classic male patients with sustained anti-agalsidase beta immunoglobulin G (IgG) antibodies (ADA); and compare the long-term effectiveness of Fabrazyme between Classic patients with lower-dose regimen and those with standard-dose regimen."

PRAC Led

Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/004993/II/0008

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "C.I.11.b: Submission of an updated RMP version 1.9 in order to provide a consolidated RMP for adjuvanted trivalent influenza vaccine

(aTIV) and adjuvanted quadrivalent influenza vaccine (aQIV), including an alignment of safety concerns for aTIV and aQIV."

Imbruvica - ibrutinib - EMEA/H/C/003791/II/0064, Orphan

Janssen-Cilag International NV, Rapporteur: Filip Josephson, "Update of the SmPC section 5.1 to include PFS2 and data from the final analysis with long term follow-up relevant to the Waldenström's macroglobulinaemia (WM) indication and section 4.8, to include the long-term safety cumulative data - following the submission of the addendum to the final clinical study report from Study PCYC-1127-CA. In addition, an amendment to section 4.4 of the SmPC to add adequate language regarding excipients with known effect and an amendment to Table 1 of the SmPC to include a footnote by cardiac failure to reflect inclusion of events with fatal outcomes were implemented. The Package Leaflet was revised accordingly."

Invokana - canagliflozin - EMEA/H/C/002649/II/0055

Janssen-Cilag International NV, Rapporteur: Martina Weise, "Update to sections 4.2 and 5.1 of the Invokana SmPC to amend posology information concerning the treatment of patients with eGFR between ≥30 and <45 mL/min/1.73 m2, whether or not albuminuria is present; the update is based on further analysis of previously submitted CANVAS data (studies DIA3008 and DIA4003).
The Applicant has also taken the opportunity to make minor editorial changes to section 4.5."

Iressa - gefitinib - EMEA/H/C/001016/II/0034

AstraZeneca AB, Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add Palmar-plantar erythrodysaesthesia syndrome to the list of adverse drug reactions (ADRs) with frequency uncommon; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1."

Kisplyx - lenvatinib - EMEA/H/C/004224/II/0039/G

Eisai GmbH, Rapporteur: Karin Janssen van Doorn, "C.I.13. Submission of a nonclinical (primary pharmacodynamics) study report-

M14014 on the Antiproliferative Activities of Lenvatinib Mesilate and Sorafenib Tosylate in VEGF-Stimulated Growth of HUVECs.
C.I.13. Submission of a nonclinical (primary pharmacodynamics) study report-W-20140845 on the Antiangiogenic Activity of Lenvatinib Mesilate and Sorafenib Tosylate in bFGF-Induced Matrigel Plug Assay in Athymic Mice."

Mavenclad - cladribine - EMEA/H/C/004230/II/0016

Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, "C.I.4 Update of section 4.8 of the SmPC in order to add hypersensitivity to the list of adverse drug reactions (ADRs) with frequency "common" based on a review of cumulative clinical and post-marketing data. The Package Leaflet is updated accordingly."

Nilemdo - bempedoic acid - EMEA/H/C/004958/II/0007

Daiichi Sankyo Europe GmbH, Rapporteur: Johann Lodewijk Hillege, "C.I.13: Submission of the final report from clinical study 1002-050 listed as a category 3 study in the RMP (MEA). This is a multicenter open-label extension (OLE) study to assess the long-term safety and efficacy of bempedoic acid 180 mg. Study 1002-050 was a roll-over extension study of a long-term (52 weeks), randomized, double-blind, controlled study (Study 1002-040, referred to as the parent study) of bempedoic acid 180 mg once daily versus placebo with a 2:1 randomization."

Nustendi - bempedoic acid / ezetimibe - EMEA/H/C/004959/II/0007

Daiichi Sankyo Europe GmbH, Rapporteur: Johann Lodewijk Hillege, "C.I.13: Submission of the final report from clinical study 1002-050 listed as a category 3 study in the RMP (MEA). This is a multicenter open-label extension (OLE) study to assess the long-term safety and efficacy of bempedoic acid 180 mg. Study 1002-050 was a roll-over extension study of a long-term (52 weeks), randomized, double-blind, controlled study (Study 1002-040, referred to as the parent study) of bempedoic acid 180 mg once daily versus placebo with a 2:1 randomization."

Ocrevus - ocrelizumab - EMEA/H/C/004043/II/0023

Roche Registration GmbH, Rapporteur: Kirstine Moll Harboe, "To update SmPC (section 5.1) with the newly available post-hoc analysis results related to the time-to-wheelchair data performed on clinical study WA25046 (ORATORIO) in the PPMS population."

Opsumit - macitentan - EMEA/H/C/002697/II/0039, Orphan

Janssen-Cilag International N.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.4, 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information of macitentan with moderate dual inhibitors of CYP3A4 and CYP2C9 based on results from a non-clinical study and a physiologically based pharmacokinetic study in healthy subjects and CYP2C9 poor metabolizers; the Package Leaflet is updated accordingly. A direct healthcare professional communication (DHPC) for this new safety information is being proposed. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Orgalutran - ganirelix - EMEA/H/C/000274/II/0046

Merck Sharp & Dohme B.V., Rapporteur: Outi Mäki-Ikola, "Update of section 4.2 of the SmPC in order to include information on handling air bubbles in the pre-filled syringes. The MAH aligned the Package Leaflet accordingly and took the opportunity to update the list of local representatives and to implement minor editorial changes in the PI."

Perjeta - pertuzumab - EMEA/H/C/002547/II/0055

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Submission of the final report from study BO25114 (JACOB). This is a double-blind, placebo-controlled, randomized, multicenter phase III study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction and gastric cancer."

Pravafenix - fenofibrate / pravastatin sodium - EMEA/H/C/001243/II/0030

Laboratoires SMB s.a., Rapporteur: Jean-Michel Race, "Update of section 4.5 of the SmPC in order to add drug-drug interaction information

with glitazones resulting in HDL cholesterol decrease, as already mentioned in the Product Information of other products containing fenofibrate 160 mg; update of sections 2 and 4.4 of the SmPC to correct the warning on lactose and to implement the wording on sodium, in line with the latest revision of the Excipients guideline. The Package Leaflet and the Labelling are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.1."	
Taltz - ixekizumab - EMEA/H/C/003943/II/0040 Eli Lilly Nederland B.V., Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC with long-term efficacy and safety data in axial spondyloarthritis from study RHBY - A multicenter, long-term extension study of 104 weeks, including a double-blind, placebo-controlled 40-week randomized withdrawal–retreatment period, to evaluate the maintenance of treatment effect of ixekizumab in patients with axial spondyloarthritis."	
Thalidomide Celgene - thalidomide - EMEA/H/C/000823/II/0066 Celgene Europe BV, Rapporteur: Alexandre Moreau, "Update of section 4.8 to include PML. This change is being introduced following the approval of version 11 of the Company Core Data Sheet (CCDS) for thalidomide. The PIL is updated accordingly."	
Xydalba - dalbavancin - EMEA/H/C/002840/II/0037 Allergan Pharmaceuticals International Limited, Rapporteur: Filip Josephson, "Submission of the final report from the microbial surveillance study 14-DUR-01, listed as a category 3 study in the RMP. This is a microbial surveillance study of dalbavancin activity tested against clinical isolates collected in Europe and United States. This submission addresses the post-authorisation measure MEA 002.3."	
WS1963 **Leganto-EMEA/H/C/002380/WS1963/0033** **Neupro-EMEA/H/C/000626/WS1963/0087**	

UCB Pharma S.A., Lead Rapporteur: Bruno Sepodes, "To update section 4.4 of the SmPC to add a warning following the update of the Company Core Data Sheet (CCDS) for rotigotine. The CCDS update consists in the addition of 2 warnings related to dopamine dysregulation syndrome and dopamine agonist withdrawal syndrome; Section 2 of the Package Leaflet is updated accordingly."

WS1976
Kisplyx-EMEA/H/C/004224/WS1976/0040
Lenvima-EMEA/H/C/003727/WS1976/0039
Eisai GmbH, Lead Rapporteur: Karin Janssen van Doorn, "C.I.13-Submission of the final nonclinical (pharmacokinetic) study report-XT205008 on the Inhibitory potential on UDP-glucuronosyltransferase 2B17 by E7080 in human liver microsomes."

B.6.10. CHMP-PRAC assessed procedures

Erleada - apalutamide - EMEA/H/C/004452/II/0009
Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 5.3 of the SmPC in order to include non-clinical information based on final results from a 26-week carcinogenicity study (TOX13540) listed as a category 3 study in the RMP. The RMP version 3.2 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.1."

EXJADE - deferasirox - EMEA/H/C/000670/II/0075
Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "The PI has been updated to remove discrepancies between SmPC and PL in sections `Pregnancy and breast-feeding' and section `Other medicines and EXJADE'. Furthermore, the Exjade SmPC and PL have been updated according to the Guidelines on excipients in the labelling and package leaflet of medicinal products for human use, Rev. 2. The MAH took also the opportunity to align the PI with the

latest QRD template v. 10.1 and update the details of local representatives in EE, LV and NL. The Annex IID has been updated to reflect the new milestone for study CICL670E2422. In addition, the EU RMP version 18.0 for Exjade has been revised to introduce following changes: · Removal of the important identified risk, "Severe cutaneous adverse reactions (including Stevens-Johnson syndrome, Toxic epidermal necrolysis and Drug reaction with eosinophilia and systemic symptoms)" · Change to the milestone for Study CICL670E2422 (Category 1) and change to RMP commitment deliverable and milestone for Study CICL670F2202 (Category 3) · Removal of the study CICL670F2429 (Category 1) due to fulfilment of the corresponding Post-Authorisation Measure · Removal of the expedited reporting requirement for the serious Adverse Drug Reactions (ADRs), 'Increase in hepatic enzymes >10 x upper limit of normal (ULN)', 'Serious rise in creatinine', 'results of renal biopsies', 'cataracts', 'hearing loss', gallstones' as agreed during PRAC PSUR Assessment (Procedure no.: EMEA/H/C/PSUSA/00000939/201910)."	
Isentress - raltegravir - EMEA/H/C/000860/II/0093 Merck Sharp & Dohme B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, "Update of section 4.6 of the SmPC in order to update safety information following pregnancy outcome data for raltegravir 400 mg film-coated tablet from prospective reports of pregnancy data with known outcome and time of raltegravir exposure. The updated RMP version 15.1 has also been submitted. In addition, the MAH took the opportunity to correct an inconsistency in the text describing the possibility to divide the scored 100 mg chewable tablet by harmonising the text of the footer of Tables 1 and 2 of the chewable tablets' SmPC .This was already identified in the procedure EMEA/H/C/000860/IB/0087 and is in line with the assessment done in the extension application for the chewable tablets EMEA/H/C/000860/X/0024/G. Finally, the contact details of Germany have	

been updated in the List of local Representatives and the PI is being brought in line with the latest QRD template (version 10.1)”	
Jakavi - ruxolitinib - EMEA/H/C/002464/II/0050 Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, “Update of sections 4.2 and 5.1 of the SmPC in order to update the posology and the method of administration as well as to include the A2201/EXPAND study CINC424A2201 (referred to as A2201 or “EXPAND” study). The changes are based on final results of a Category 3 clinical study, phase Ib study to fulfil an RMP post approval commitment. This is a dose-finding study intended to establish the maximum safe starting dose (MSSD) of ruxolitinib tablets administered orally to patients with MF in the previous unstudied population of patients who had baseline platelet counts ≥50×109/L and <100×109/L. The Package Leaflet is updated accordingly. The RMP version 12 has also been submitted based on the results of Study A2201 (category 3, additional pharmacovigilance activity), the review of safety concerns in compliance with the Good Pharmacovigilance Practices Module V, Revision 2, as well as recent PRAC outcome on PSUR (Procedure no.: EMEA/H/C/PSUSA/00010015/202002, CHMP Opinion dated 15-Oct-2020).”	
Perjeta - pertuzumab - EMEA/H/C/002547/II/0054 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Hans Christian Siersted, “Submission of the final report from study MO28047 (PERUSE) listed as an obligation in the Annex II of the Product Information. This is a multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurrent) breast cancer. The RMP (version 13.0) is proposed to be updated accordingly.”	
Pyramax - pyronaridine / artesunate - EMEA/H/W/002319/II/0023/G Shin Poong Pharmaceutical Co., Ltd., Rapporteur: Jean-Michel Race, PRAC	

Rapporteur: Adrien Inoubli, "Grouping of variations providing the final clinical study reports (CSR) of two completed studies:
- Study SP-C-021-15: A Phase IIIb/IV cohort event monitoring study conducted in Central Africa to evaluate the safety in patients after the local registration of Pyramax (CANTAM study). This study is a Category 3 Required Additional Pharmacovigilance Activity described in the RMP (MEA 013).
- SP-C-026-18: A Randomized Open-Label Exploratory Study to Determine The Efficacy of Different Treatment Regimens of Pyramax (Pyronaridine-Artesunate) In Asymptomatic Carriers Of Plasmodium Falciparum Monoinfections. This non-imposed study was conducted in Gambia and Zambia and compared asymptomatic subjects with parasitaemia dosed according to the approved label of 3-day dosing with 2-day and 1-day dosing. There have been no new safety findings from the study but the RMP has been updated to reflect its details.
As a result of the additional clinical data, corresponding changes to the Product Information (SmPC and PL) are proposed with the Grouping.
RMP version 17 has also been submitted, updated to reflect the results of both above-mentioned CSRs, and converted to the new RMP integrated template format (Rev 2.0.1)."

Qtern - saxagliptin / dapagliflozin - EMEA/H/C/004057/II/0031

AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ilaria Baldelli, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to reflect new data based on final results from study D1693C00001 (DECLARE). This is a multi-centre, randomised, double-blind, placebo-controlled study to evaluate the effect of dapagliflozin on cardiovascular (CV) and renal outcomes in patients with T2DM with or without established CV disease. The labelling and Package Leaflet (PL) are updated accordingly. The Risk Management Plan (RMP) v5.1 has also been updated to version. The MAH took the opportunity to make additional editorial changes to the PI."

Revolade - eltrombopag - EMEA/H/C/001110/II/0063

Novartis Europharm Limited, Rapporteur: Maria

Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, "Update of sections 4.2, 4.8 and 5.2 of SmPC to clarify dosing recommendations to ensure accurate treatment of patients of 'East-/Southeast-Asian' ancestry and to correct the ADR list based on currently available data, which was previously submitted and reviewed. Update of section 4.4 of the SmPC in line with the 'Excipients in the labelling and package leaflet of medicinal products for human use'. The Package leaflet has been updated accordingly. An updated RMP has been submitted to update the final due date i.e. the date for the provision of the primary study report of CETB115E2201 (category 3) in the RMP and removal of important safety concerns, already endorsed by PRAC in the PSUSA procedure (EMEA/H/C/PSUSA/00001205/201809)."	
Steglujan - ertugliflozin / sitagliptin - EMEA/H/C/004313/II/0015 Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC for Steglujan in order to update clinical information following final results from the VERTIS CV study (protocol 8835-004/B1521021) listed as a category 3 study in the RMP. This is a multi-centre, multi-national, randomised, double-blind, placebo-controlled study to evaluate the effect of ertugliflozin on cardiovascular risk in adult patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity include an editorial change in section 4.1 of the SmPC."	
Tasigna - nilotinib - EMEA/H/C/000798/II/0107 Novartis Europharm Limited, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Hans Christian Siersted, "Submission of the 5 year data including data on late relapses from the ongoing studies ENESTfreedom (CAMN107I2201): A Phase II, single-arm, open-label, multicenter nilotinib TFR study in patients with BCR-ABL1 positive CML-CP, who had achieved durable minimal residual disease (MRD) status on first-line nilotinib treatment and ENESTop	

(CAMN107A2408): A Phase II, single-arm, open-label, multicenter study, evaluating TFR in patients with BCR-ABL1-positive CML-CP who achieved a sustained molecular response of MR4.5 on nilotinib treatment after switching from imatinib to nilotinib.
Consequently, the RMP version 23 is being updated to remove the additional pharmacovigilance activity 'collection and submission of data on late relapses from the ongoing studies ENESTfreedom (CAMN107I2201) and ENESTop (CAMN107A2408)' and the safety concern 'risk of resistance (in TFR)'."

TECFIDERA - dimethyl fumarate - EMEA/H/C/002601/II/0069/G

Biogen Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "C.I.4 type II variation: Update of section 4.8 of the SmPC in order to add rhinorrhoea to the list of adverse drug reactions (ADRs) with frequency unknown based on a systematic review of information from clinical and non-clinical studies, post-marketing data and scientific literature. The Package Leaflet has been updated accordingly.
C.I.4 type II variation: Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study 109MS303 (ENDORSE) listed as a category 3 study in the RMP. This is a dose-blind, multicenter, extension study to determine the long-term safety and efficacy of two doses of BG00012 monotherapy in subjects with Relapsing-Remitting Multiple Sclerosis. The RMP version 11.1 has also been submitted."

Trumenba - meningococcal group B vaccine (recombinant, adsorbed) - EMEA/H/C/004051/II/0032

Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné, "C.I.4 To update sections 4.8 and 5.1 of the SmPC following the interim data from the primary vaccination phase (Stage 1) of study B1971057; this is a Phase 3, randomised, active-controlled, observer-blinded study to assess the immunogenicity, safety, and tolerability of bivalent rLP2086 when administered as a 2-dose regimen and a first-in-human study to describe the immunogenicity,

safety, and tolerability of a bivalent rLP2086 containing pentavalent vaccine (MenABCWY) in healthy subjects ≥10 to <26 years of age. The MAH takes the opportunity to implement some editorial changes in section 4.4 of the SmPC and sections 2, 3 and 6 of the Package Leaflet in order to comply with the excipients guideline for Sodium Chloride."

Vargatef - nintedanib - EMEA/H/C/002569/II/0037

Boehringer Ingelheim International GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Agni Kapou, "Submission of the final report from study LUME BioNIS listed as an obligation in the Annex II of the Product Information. This is a non-interventional study in patients eligible for treatment with Vargatef to explore whether genetic or genomic markers (alone or combined with clinical covariates) could be used to predict overall survival. The Annex II and the RMP version 8.0 are updated accordingly."

Vimizim - elosulfase alfa - EMEA/H/C/002779/II/0034, Orphan

BioMarin International Limited, PRAC Rapporteur: Rhea Fitzgerald, "Submission of an updated RMP version 5 in order to update the safety specifications (epidemiology of indication and target populations, exposures in clinical trials and post marketing) and the pharmacovigilance plan (routine and additional pharmacovigilance activities). Deletion of a training material in section V.1 and addition of healthcare provider educational materials and process indicator to evaluate the distribution of the educational materials. Part VI and VII have been updated accordingly. The RMP has also been updated in line with EU RMP template (revision 2.0.1)."

Xeljanz - tofacitinib - EMEA/H/C/004214/II/0028

Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, "Submission of the final report on Biospecimen testing study, listed as a category 3 study in the RMP. This is an exploratory study to assess biomarkers related to VTE events in Study A3921133. The RMP version 14.1 has also been submitted."

WS1965/G

Hexacima-EMEA/H/C/002702/WS1965/0110/G
Hexaxim-EMEA/H/W/002495/WS1965/0115/G
Hexyon-EMEA/H/C/002796/WS1965/0114/G
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus, Lead PRAC Rapporteur: Brigitte Keller-Stanislawski, "C.I.4 (type II): Update of section 5.1 of the SmPC in order to describe the persistence of anti-HBs antibodies in subjects 6 years of age having received a hexavalent vaccine based on the final results from study A3L00052; this is a phase IV, open-label, multi-centre study in children previously vaccinated in Study A3L38a with 3 doses of either Hexacima/Hexyon/Hexaxim (Group 1) or Infanrix Hexa (Group 2).
C.I.4 (type II): Update of sections 4.4 and 5.1 of the SmPC in order to reword safety and immunogenicity information regarding individuals with immunodeficiency based on the final results from study A3L44; this is a Phase III, single centre, open-label, two-arm study including HIV-exposed infected and uninfected infants vaccinated with a 3-dose infant primary series (at 6, 10, and 14 weeks of age) and a booster dose (at 15 to 18 months of age) with Hexacima/Hexyon/Hexaxim in Republic of South Africa. The updates to the SmPC were requested following assessment of these data by Article 46, EMEA/H/C/002702/P46/036 (Hexacima), EMEA/H/C/002796/P46/034 (Hexyon) and EMEA/H/W/002495/P46/036 (Hexaxim).
C.I.z (type IB): Updated of section 4.4 of the SmPC in order to include syncope within the precautions for use. The package leaflet is updated accordingly. In addition, the WSA took the opportunity to update the list of local representatives in the Package Leaflet.
The RMP version 13.0 has also been submitted."

B.6.11. PRAC assessed procedures

PRAC Led
Adasuve - loxapine - EMEA/H/C/002400/II/0032
Ferrer Internacional s.a., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "To submit the final clinical

study report (CSR) for Study AMDC- 204-401 EU PASS: Post-authorisation Observational Study to Evaluate the Safety of ADASUVE - Staccato
loxapine for inhalation- in Agitated Persons in Routine Clinical Care."

PRAC Led

Cetrotide - cetrorelix -
EMEA/H/C/000233/II/0075

Merck Europe B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of an updated RMP (version 5.2), in order to bring it in line with revision 2 of GVP module V on 'Risk management systems' including consequential removal of a number of important identified risks and important potential risk of congenital anomalies, as well as removal of missing information on infertile premenopausal women; information in the RMP has been revised based on the most recent data and the post-marketing exposure was updated."

PRAC Led

Conbriza - bazedoxifene -
EMEA/H/C/000913/II/0054

Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Update of Risk Management Plan (RMP) to include updated study milestones and to revise the RMP format in line with latest Good Pharmacovigilance Practices Guidance Module V, revision 2 guidelines."

PRAC Led

Eylea - aflibercept -
EMEA/H/C/002392/II/0068

Bayer AG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "The submission contains the study report of the PASS study Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Europe: A Follow-up Physician survey.
The study was requested as a category 3 study. RMP has been updated accordingly (version 27.1)."

PRAC Led

Fabrazyme - agalsidase beta -
EMEA/H/C/000370/II/0120

Genzyme Europe BV, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final report following CHMP conclusions on the related post-authorisation measure (FU2 57.4) from the MAH Fabry Pregnancy Sub-registry, a multicenter, international, longitudinal, observational study on pregnancy outcomes for any pregnant woman enrolled in the MAH Fabry Registry who also consented to participate in the Sub-registry, regardless of whether she was receiving disease therapy (such as ERT with agalsidase beta) and irrespective of the commercial product with which she may have been treated. This study is listed as a category 3 in the RMP."

PRAC Led

Mavenclad - cladribine - EMEA/H/C/004230/II/0015

Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, PRAC-CHMP liaison: Bruno Sepodes, "C.I.11.b type II submission of an updated RMP version 1.4 in order to align to the RMP template Rev. 2. In addition, the MAH took the opportunity to include long-term safety data from the completed PREMIERE registry and remove the completed study from the pharmacovigilance plan, update of the status of the post-approval safety studies CLARION and CLEAR and update the RMP with the most recent post-approval safety data from the PBRER."

PRAC Led

Ovaleap - follitropin alfa - EMEA/H/C/002608/II/0034

Theramex Ireland Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final study report for SOFIA (Safety of Ovaleap (Follitropin alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies, XM17-WH-5005) listed as a category 3 study in the RMP. This is a multi-national, comparative, prospective, non-interventional, observational cohort study. The RMP version 3.3 has also been submitted."

PRAC Led

Revatio - sildenafil -

EMEA/H/C/000638/II/0091
Upjohn EESV, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 7.0 in order to update the summary of safety concerns in line with GVP module V rev 2 guidelines. Consequently, the educational programme for the risk of hypotension is proposed to be terminated."

PRAC Led
WS1970
Eucreas-EMEA/H/C/000807/WS1970/0081
Galvus-EMEA/H/C/000771/WS1970/0067
Icandra-EMEA/H/C/001050/WS1970/0084
Jalra-EMEA/H/C/001048/WS1970/0069
Xiliarx-EMEA/H/C/001051/WS1970/0067
Zomarist-EMEA/H/C/001049/WS1970/0083
Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Kristina Dunder, "RMP (Risk Management Plan) update to version 15.0 and amendment to Annex II of SmPC. The RMP update includes removal of RMP topics as per EMA GVP Module V, rev 2 guidelines and to align with the recommendations in the Galvus/Eucreas EMEA/H/C/PSUSA/00003113/201802."

B.6.12. CHMP-CAT assessed procedures

Alofisel - darvadstrocel - EMEA/H/C/004258/II/0021, Orphan, ATMP
Takeda Pharma A/S, Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder

Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0030, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, "Update of section 5.1 of the SmPC to include the complete data set (updated overall survival analysis) of study CCTL019B2205J, a Phase II, single arm, multicenter study to determine the efficacy and safety of Kymriah in paediatric

subjects with relapsed or refractory B-cell ALL. The clinical results have already been assessed in procedure EMA/H/C/004090/P46/011. In addition, the final ATC code for tisagenlecleucel (L01XX71) has been added as an editorial change.”
Yescarta - axicabtagene ciloleucel - EMEA/H/C/004480/II/0030, Orphan, ATMP Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus
Yescarta - axicabtagene ciloleucel - EMEA/H/C/004480/II/0031, Orphan, ATMP Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus
Yescarta - axicabtagene ciloleucel - EMEA/H/C/004480/II/0033, Orphan, ATMP Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS1946 **Copalia-EMEA/H/C/000774/WS1946/0113** **Dafiro-EMEA/H/C/000776/WS1946/0117** **Exforge-EMEA/H/C/000716/WS1946/0112** Novartis Europharm Limited, Lead Rapporteur: Kirstine Moll Harboe
WS1949/G **Mosquirix-EMEA/H/W/002300/WS1949/0050/G** **Shingrix-EMEA/H/C/004336/WS1949/0038/G** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke
WS1957/G

Hexacima-EMEA/H/C/002702/WS1957/0111/G
Hexaxim-EMEA/H/W/002495/WS1957/0116/G
Hexyon-EMEA/H/C/002796/WS1957/0115/G
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

WS1966
Incresync-EMEA/H/C/002178/WS1966/0035
Vipdomet-EMEA/H/C/002654/WS1966/0030
Vipidia-EMEA/H/C/002182/WS1966/0025
Takeda Pharma A/S, Lead Rapporteur: Johann Lodewijk Hillege

WS1968
Anoro Ellipta-EMEA/H/C/002751/WS1968/0033
Laventair Ellipta-EMEA/H/C/003754/WS1968/0036
Relvar Ellipta-EMEA/H/C/002673/WS1968/0047
Revinty Ellipta-EMEA/H/C/002745/WS1968/0045
GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro

WS1973
Infanrix hexa-EMEA/H/C/000296/WS1973/0291
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS1977
Enurev Breezhaler-EMEA/H/C/002691/WS1977/0033
Seebri Breezhaler-EMEA/H/C/002430/WS1977/0033
Tovanor Breezhaler-EMEA/H/C/002690/WS1977/0037
Novartis Europharm Limited, Lead Rapporteur: Kirstine Moll Harboe

WS1983/G
Delstrigo-EMEA/H/C/004746/WS1983/0021/G
Pifeltro-EMEA/H/C/004747/WS1983/0015/G
Merck Sharp & Dohme B.V., Lead Rapporteur:

Filip Josephson
WS1985 **Aflunov-EMEA/H/C/002094/WS1985/0067** **Foclivia-EMEA/H/C/001208/WS1985/0063** Seqirus S.r.l, Lead Rapporteur: Armando Genazzani
WS1992/G **Nuwiq-EMEA/H/C/002813/WS1992/0038/G** **Vihuma-EMEA/H/C/004459/WS1992/0020/G** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus
WS1996 **Rixathon-EMEA/H/C/003903/WS1996/0046** **Riximyo-EMEA/H/C/004729/WS1996/0046** Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus
WS1999 **Nuwiq-EMEA/H/C/002813/WS1999/0040** **Vihuma-EMEA/H/C/004459/WS1999/0022** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

F.1. Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended

F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. Ongoing procedures

G.3. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.3.1. List of procedures concluding at 07-10 December 2020 CHMP plenary:

G.3.2. List of procedures starting in December 2020 for January 2021 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address